Subcellular specificity of cannabinoid effects in striatonigral circuits

Edgar Soria-Gomez, Antonio Pagano Zottola, Yamuna Mariani, Tiffany Desprez, Massimo Barresi, Itziar Bonilla-del Río, Carolina Muguruza, Morgane Le Bon-Jego, Francisca Julio-Kalajzić, Robyn Flynn, et al.

► To cite this version:

Edgar Soria-Gomez, Antonio Pagano Zottola, Yamuna Mariani, Tiffany Desprez, Massimo Barresi, et al.. Subcellular specificity of cannabinoid effects in striatonigral circuits. *Neuron*, 2021, 109 (9), pp.1513-1526.e11. 10.1016/j.neuron.2021.03.007 . hal-03375577

HAL Id: hal-03375577

<https://hal.science/hal-03375577>

Submitted on 15 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SUBCELLULAR SPECIFICITY OF CANNABINOID EFFECTS IN STRIATONIGRAL CIRCUITS

Edgar Soria-Gomez^{1,2,3,4,5,15,16*}, Antonio C. Pagano Zottola^{1,2,15}, Yamuna Mariani^{1,2,15}, Tiffany Desprez^{1,2}, Massimo Barresi^{2,6}, Itziar Bonilla-del-Río^{3,4}, Carolina Muguruza⁷, Morgane Le Bon-Jego^{2,6}, Francisca Julio-Kalajzić^{1,2}, Robyn Flynn^{8,9}, Geoffrey Terral^{1,2}, Ignacio Fernández-Moncada^{1,2}, Laurie M. Robin^{1,2}, Jose F. Olivera da Cruz^{1,2}, Simone Corinti^{1,2}, Yasmine Ould Amer¹⁰, Julia Goncalves^{1,2}, Marjorie Varilh^{1,2}, Astrid Cannich^{1,2}, Bastien Redon^{1,2}, Zhe Zhao^{1,2}, Thierry Lesté-Lasserre^{1,2}, Peggy Vincent^{1,2}, Tarson Tolentino-Cortes¹¹, Arnau Busquets-García^{1,2}, Nagore Puente^{3,4}, Jaideep S. Bains⁹, Etienne Hebert-Chatelain¹⁰, Gabriel Barrera-Gómez¹¹, Francis Chaouloff^{1,2}, Alexander W. Lohman^{8,9,12}, Luis F. Callado^{7,13}, Pedro Grandes^{3,4,14}, Jerome Baufreton^{2,6}, Giovanni Marsicano^{1,2,16,17*}, Luigi Bellocchio^{1,2,16*}

¹INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; ²University of Bordeaux; ³Dept. of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; ⁴Achucarro Basque Center for Neuroscience, Leioa, Spain; ⁵IKERBASQUE, Basque Foundation for Science; ⁶IMN-UMR CNRS 5293 Neurodegenerative Diseases Institute, Bordeaux, France; ⁷Dept. of Pharmacology, University of the Basque Country UPV/EHU, Leioa, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain. ⁸Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, AB Canada; ⁹Hotchkiss Brain Institute, University of Calgary, Calgary, AB Canada; ¹⁰Canada Research Chair in Mitochondrial Signaling and Physiopathology, Department of Biology, University of Moncton, NB Canada; ¹¹Department of Research and Development, IMG Pharma Biotech S.L., Derio, Spain; ¹²Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB Canada; ¹³Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; ¹⁴Division of Medical Sciences, University of Victoria, Victoria, BC, Canada.

¹⁵ These authors contributed equally

¹⁶ Senior Authors

¹⁷ Lead Contact

*Correspondence to: Edgar Soria-Gomez, edgar.soria@achucarro.org
Luigi Bellocchio, luigi.bellocchio@inserm.fr
Giovanni Marsicano, giovanni.marsicano@inserm.fr

SUMMARY

Recent advances in neuroscience positioned brain circuits as the key units controlling behavior, implying that their positive or negative modulation necessarily leads to specific behavioral outcomes. However, emerging evidence suggests that activation or inhibition of specific brain circuits can actually produce multimodal behavioral outcomes. Here we show that, in the same neuronal circuit, activation of a receptor at different subcellular locations can determine distinct specific behaviors. Pharmacological activation of type-1 cannabinoid receptors (CB₁) in the striatonigral circuit elicits both antinociception and catalepsy in mice. The reduction of nociception depends on the activation of plasma membrane-residing CB₁ receptors (pmCB₁), leading to inhibition of PKA activity and Substance-P release. Conversely, mitochondrial-associated CB₁ receptors (mtCB₁) located at the same terminals mediate cannabinoid-induced catalepsy through decrease of intra-mitochondrial PKA-dependent cellular respiration and synaptic transmission. Thus, subcellular-specific CB₁ receptor signaling within striatonigral circuits determines multimodal control of behavior.

KEYWORDS: CB₁ receptor, catalepsy, antinociception, THC, mitochondria, substantia nigra, PKA, Substance-P.

1 INTRODUCTION

2 The cannabinoid receptor type-1 (CB₁) is the main target of cannabinoid
3 compounds. Cannabinoids possess high therapeutic potentials (Cohen et al.,
4 2019), particularly in the management of pain sensitivity (Donvito et al., 2018).
5 However, because of significant side-effects (e.g., cognitive and motor
6 dysfunctions; Borgelt et al., 2013; Prashad and Filbey, 2017) their medical and
7 recreational use is under intense scrutiny (Cohen et al., 2019). In particular,
8 activation of CB₁ receptors impairs motor control (Giuffrida and Seillier, 2012;
9 Monory et al., 2007) and cataleptic-like effects are considered the leading
10 cause of vehicle accidents caused by human cannabis consumption (Martin et
11 al., 2017).

12 Basal ganglia circuits, classically associated with motor control, are now studied
13 in different contexts, including cognition and nociception. In particular,
14 striatonigral circuits formed by dopamine receptor type-1 (D₁)-positive striatal
15 medium spiny neurons projecting to the substantia nigra pars reticulata (SNr)
16 play crucial roles in motor regulation (Freeze et al., 2013) and participate in
17 nociception (Taylor et al., 2016). Indeed the SNr represents the ideal hub
18 coordinating voluntary movement and nociceptive responses according to the
19 different inputs received (Zhou et al., 2016), and displays one of the highest
20 levels of CB₁ receptor protein expression in the brain (Marsicano and Kuner,
21 2008).

22 Neuronal CB₁ receptors are predominantly associated with presynaptic terminal
23 plasma membranes (pmCB₁; Ibsen et al., 2017) and their activation mainly

1 results in the fine-tuned regulation of neurotransmitter and neuropeptide release
2 (Busquets-Garcia et al., 2018). However, recent data indicate that functional
3 CB₁ receptors are also present in intracellular compartments, particularly in
4 association with mitochondria (mtCB₁; Benard et al., 2010; Busquets-Garcia et
5 al., 2018; Hebert-Chatelain et al., 2016; Jimenez-Blasco et al., 2020; Koch et
6 al., 2015), where they modulate bioenergetic and memory processes (Hebert-
7 Chatelain et al., 2016). Indeed, normal mitochondrial functions are required for
8 proper synaptic transmission underlying behavioral control (Francisco et al.,
9 2020; Kanellopoulos et al., 2020; Rangaraju et al., 2014).

10 The double subcellular functional localization of CB₁ receptors in striatonigral
11 circuits suggests that cannabinoids might exert different effects not only by
12 altering the functions of different cell types and brain circuits, but also by
13 impacting different subcellular processes within the same circuits. Thus, here
14 we used the diverse distribution of CB₁ receptors as a tool to investigate
15 whether subcellular constraints in the same neuronal circuit can determine
16 multimodal behavioral control.

17 **RESULTS**

18 **Striatonigral CB₁ receptors mediate cannabinoid-induced motor** 19 **impairments and antinociception**

20 Cannabinoid agonists dose-dependently decrease motor activity and induce
21 antinociception through the activation of central CB₁ receptors (Metna-Laurent
22 et al., 2017; Monory et al., 2007). To test whether CB₁ receptor signaling in the
23 SNr is responsible for these effects, we locally infused (**Figure S1A**) the CB₁

1 receptor-selective antagonist AM251 in mice systemically treated
2 (intraperitoneal, i.p.) with the plant-derived CB₁ receptor agonist Δ^9 -
3 tetrahydrocannabinol (THC, 10 mg/kg). AM251 fully blocked the THC-induced
4 reduction in locomotor activity in the open field (**Figure S1B**), catalepsy in the
5 horizontal-bar test (**Figure 1A**) and antinociception in the hot-plate test (**Figure**
6 **1B**), indicating that activation of CB₁ receptors in this brain region is necessary
7 for these effects. As a control, voluntary or accidental misplacement of the
8 cannulas to brain areas just adjacent to the SNr (**Figure S1A**) eliminated any
9 impact of AM251 on THC-induced catalepsy, antinociception or hypolocomotion
10 (**Figure 1A, 1B and S1B**), clearly indicating the local specificity of the effect.

11 The SNr receives direct (striatonigral) and indirect (striatopallidal - pallidonigral)
12 information from striatal medium spiny neurons (MSNs). MSNs belonging to the
13 direct pathway preferentially express dopamine D₁R receptor, whereas the
14 indirect pathway ones are identified by the expression of dopamine D₂R
15 receptor, although in the external segment of the Globus Pallidus (GPe) there
16 are some collateral D₁R-positive projections (Freeze et al., 2013). Interestingly,
17 CB₁ receptors are abundantly expressed by both neuronal populations
18 (Fernandez-Ruiz et al., 2011). To identify which subpopulation of CB₁ receptors
19 are responsible for the antinociceptive and motor effects of THC, we used an
20 intersectional recombinase approach (Zhao et al., 2020). We injected a
21 recombinant adeno-associated virus (rAAV) expressing the Cre recombinase
22 protein in a flipase (FLP)-dependent manner (AAV-FRT-iCre-EGFP) in the
23 striatum of mice carrying a “floxed” CB₁ gene (*CB₁-flox*; Marsicano et al., 2003).
24 Simultaneously, a retrograde rAAV expressing flipase (AAV-retro-FLP-BLFP)

was administered into either the GPe or the SNr (**Figure S1C**). Thus, we obtained the expression of the Cre recombinase in striatopallidal or striatonigral neurons of *CB₁*-flox mice, leading to the generation of ST-GP-*CB₁*-KO or ST-SN-*CB₁*-KO mutants that carrying the deletion of the receptor gene in either populations, respectively (**Figure S1C**). *In situ* hybridization coupled to GFP immunostaining for Cre detection showed that the recombinase was preferentially expressed in D₁R neurons over D₂R in ST-SN-*CB₁*-KO (D₁R/Cre cells 68.5±2.8%; D₂R/Cre cells 9±1%) with an opposite situation in ST-GP-*CB₁*-KO (D₁R/Cre cells 21.7±1.9%; D₂R/Cre cells 42.5±5.1%).

Deletion of *CB₁* receptor gene in these models was confirmed by double *in situ* hybridization experiments, which showed preferential loss of *CB₁* receptor expression by D₁R-expressing striatal neurons in ST-SN-*CB₁*-KO mice and by D₂R expressing neurons in the ST-GP-*CB₁*-KO mice (**Figure S1D**). Accordingly, ST-SN-*CB₁*-KO showed a consistent reduction of *CB₁* immunoreactivity in the SNr whereas in ST-GP-*CB₁*-KO, *CB₁* protein was selectively reduced in the GPe (**Figure 1C**).

Whereas ST-GP-*CB₁*-KO mice responded to THC treatment similar to control animals, ST-SN-*CB₁*-KO littermates did not display either catalepsy or antinociception upon THC administration (**Figure 1D and 1E**). On the other hand, the hypolocomotor effect of THC was maintained upon both manipulations (**Figure S1E**), suggesting that other subpopulations of SNr *CB₁* receptors are likely involved in this effect. These data indicate that activation of *CB₁* receptors expressed at striatonigral, but not striatopallidal, terminals is

necessary for THC-induced antinociception and catalepsy, revealing a common anatomical target for these effects.

Cannabinoid-induced antinociception relies on activation of striatonigral pmCB₁ and regulation of Substance-P/NK₁ receptor activity

THC and AM251 are lipophilic molecules, which easily cross biological membranes, thereby potentially acting at both plasma membrane and intracellular CB₁ receptors. To distinguish between the contributions of these two pools of CB₁ receptors to the THC effects in the SNr, we locally administered the CB₁ receptor antagonist Hemopressin (Hp; Heimann et al., 2007). Hp is a peptide compound, which is unable to cross the plasma membrane (Benard et al., 2012) and, thereby, antagonizes only pmCB₁ receptors but not intracellular ones (Benard et al., 2012; Rozenfeld and Devi, 2008). Intra-SNr administration of Hp did not exert any effect by itself and it was not able to reverse THC-induced catalepsy (**Figure 1F**), but it strongly reduced the antinociceptive effect of THC (**Figure 1G**). Striatonigral neurons are known to release several neuropeptides, including Substance-P (Deniau et al., 2007; Johnson et al., 2016), which promotes pain perception *via* central activation of its main target, the type-1 neurokinin receptor (NK₁; Steinhoff et al., 2014). Interestingly, inhibition of NK₁ signaling can decrease pain reactions induced by systemic CB₁ receptor blockade (Darmani and Pandya, 2000), and some evidence suggests a negative role of CB₁ receptor signaling in Substance-P

1 production and release in the spinal cord and the striatum (Lever and
2 Malcangio, 2002; Steiner et al., 1999). To test whether Substance-P signaling in
3 the SNr might underlie THC-induced antinociception, we systemically
4 administered the selective NK₁ receptor agonist GR73632 (Ray et al., 2009), in
5 combination with THC. GR73632 (75 µg/kg) alone had no effect in any test, and
6 it did not alter the cataleptic effect of THC (**Figure S1F**). However, this
7 treatment blocked the antinociceptive effect of the cannabinoid (**Figure S1G**).
8 Then, in order to verify that the interaction between CB₁ and NK₁ receptors
9 occurs in the SNr, GR73632 was locally injected before systemic THC
10 treatment. This treatment did not alter THC-induced catalepsy (**Figure 1H**), but,
11 strikingly, it fully abolished the antinociceptive effect of THC (**Figure 1I**). These
12 data show that cannabinoid-induced antinociception involves Substance-P
13 signaling, suggesting that activation of CB₁ receptors might reduce the release
14 of the neuropeptide at striatonigral terminals. To test this hypothesis, we
15 established an *ex vivo* “sniffer cells” approach (**Figure S1H**), which has been
16 already successfully used to detect the release of other neuropeptides in real
17 time (Zaelzer et al., 2018). We transfected HEK-293T cells with 2 plasmids for
18 co-expression of NK₁ receptor together with the calcium indicator GCaMP6s
19 (**Figure S1H**) to obtain cells capable of detecting exogenously applied
20 Substance-P in a very sensitive (EC₅₀, 5.1 nM) and specific way (**Figure S1H**
21 **and S1I**). These cells were then seeded over acute sagittal brain slices
22 containing the striatonigral pathway (**Figure 1J**). After 2-hour rest to allow
23 cellular adhesion to the slices, GCaMP6s fluorescence was imaged (Zaelzer et
24 al., 2018) (**Figure 1J**) before and after electrical stimulation of the striatonigral
25 afferents. This manipulation elicited a marked increase in GCaMP6s

fluorescence in cells placed above the SNr (**Figure 1K, S1J, S1K, S1L, S1M**), indicating an increase in Substance-P release. The increase in fluorescence is specific for the peptide, since is absent when slices are treated with cells only expressing GCaMP6s (**Figure S1J and S1L**) and it was blocked by the NK₁ selective antagonist CP122721 (**Figure S1K and S1L**). Strikingly, application of the cannabinoid agonist WIN55,212-2 (WIN) dramatically reduced electrically evoked Substance-P release in wild type mice (**Figure 1K and S1M**), but not in CB₁-KO littermates (**Figure 1K**). WIN did not affect the response to exogenous peptide (**Figure S1N**), showing that its effect in slices was due to a CB₁ receptor-mediated decrease of Substance-P release.

To further confirm the striatonigral origin of Substance-P release as well as its modulation by cannabinoids, we coupled the sniffer cells approach to optogenetic stimulation (Zaelzer et al., 2018). For this aim, we virally expressed the red-activated channelrhodopsin ChrimsonR (Klapoetke et al., 2014) in D₁R-Cre positive cells (Lemberger et al., 2007) of the striatum and then we conducted sniffer experiments in SNr slices (**Figure 1L**). As technical validations of the approach, we also performed patch clamp experiments in SNr neurons upon light stimulations. As expected based on the partial spectrum overlapping of the used light wavelength (Klapoetke et al., 2014), the application of the blue light to record calcium levels in the sniffer cells induced a slight activation of Chrimson and triggered-GABAergic currents which, however, had a much lower amplitude than the ones triggered by the red light (**Figure S1O**). Thus, some experiments had to be discarded because the blue-light stimulation was able to saturate the subsequent red-light-induced Substance-P

1 release. Nevertheless, Chrimson activation by red-light triggered above-
2 baseline calcium responses in sniffer cells in approximately 50% of the
3 experiments. In these conditions, calcium responses indicating Substance-P
4 release were drastically reduced by the application of WIN (**Figure 1M**),
5 similarly as previously observed with electrical stimulation.

6 Altogether, these data indicate that pmCB₁ receptors at D₁R-positive
7 striatonigral terminals are responsible for THC-induced antinociception,
8 involving the modulation of Substance-P/NK₁ signaling. Additionally, these
9 results point out a different mechanism for the cataleptic effect, which likely
10 involves intracellular CB₁ receptors in the SNr.

11 **Subcellular localization of CB₁ receptors in the SNr**

12 To investigate the intracellular distribution of the CB₁ receptor in the SNr, we
13 used immunogold electron microscopy (Puente, 2019). The majority of CB₁
14 receptor protein in the SNr of WT mice was associated to the plasma
15 membrane (pmCB₁) of synaptic terminals (**Figure 2A-C and S2A**).
16 Quantifications of gold particles using stringent parameters to identify
17 mitochondrial-localized immunoreactivity (Puente, 2019) revealed that CB₁
18 receptors in the SNr are anatomically associated to mitochondrial membranes
19 (mtCB₁) with a density of approximately 3 particles per 20 μm² (**Figure 2A-D**
20 **and S2A**). Moreover, approximately 10% of total mitochondria analyzed were
21 labeled with CB₁ receptor in WT mice (**Figure 2A-E and S2A**). Conversely, only
22 background levels of CB₁ immunoreactivity was detected in any analyzed
23 compartment of CB₁-KO mice (**Figure 2A-E and S2A**), clearly demonstrating
24 the existence of mtCB₁ in striatonigral terminals.

1 **Generation of DN22-CB₁-KI mutant mice, lacking mtCB₁ receptors**

2 We previously showed that a mutant version of the CB₁ protein lacking the first
3 22 amino acids (called DN22-CB₁) is neither anatomically nor functionally
4 associated to mitochondrial membranes, nevertheless maintaining its other
5 functions (e.g. at plasma membrane; Hebert-Chatelain et al., 2016). Thus, we
6 generated a new knock-in mutant mouse line (called DN22-CB₁-KI; Pagano
7 Zottola et al., 2020), in which the wild-type CB₁ receptor gene is replaced by the
8 coding sequence of the DN22-CB₁ protein (**Figure S2B**). Quantifications of CB₁
9 receptor mRNA (by qRT-PCR) and protein (by immunofluorescence) revealed
10 no significant differences between WT and DN22-CB₁-KI mice in many different
11 brain regions (**Figure S2C and S2D**). Counting of gold particles in immuno-
12 electron microscopy experiments indicated that the total amount of CB₁ receptor
13 protein in the SNr was not significantly different between DN22-CB₁-KI and WT
14 littermates (**Figure 2F, 2G and S2D**). Similarly, the levels of pmCB₁ were not
15 impacted by the mutation (**Figure 2F, 2H and S2D**). However, the density of
16 mitochondrial-associated mtCB₁ receptors and the percentage of CB₁-positive
17 mitochondria were significantly lower in DN22-CB₁-KI mice as compared to WT
18 littermates, reaching levels undistinguishable from global CB₁-KO mice (**Figure**
19 **2F, 2I, 2J and S2D**). To test the ability of DN22-CB₁ receptors to activate G
20 protein signaling, we performed [³⁵S]GTPγ binding assays upon stimulation with
21 the cannabinoid agonist WIN in cortical, hippocampal and midbrain extracts
22 from WT, CB₁-KO, and DN22-CB₁-KI mice (**Figure 2K**). The DN22-CB₁ mutant
23 was as efficient as its wild-type cognate in triggering G protein activation
24 (**Figure 2K**). These results were also confirmed by *in situ* [³⁵S]GTPγ binding
25 assays in other brain regions (**Figure S2E and S2F**). Moreover,

1 autoradiographic analyses of [³H]CP55.940 cannabinoid agonist binding in
2 parallel sections did not identify any significant difference between the two
3 genotypes (**Figure S2G and S2H**). Thus, DN22-CB₁-KI mice display normal
4 binding of cannabinoid ligands and subsequent activation of G-protein
5 signaling.

6 Oxygen consumption assays in substantia nigra (SN) homogenates revealed
7 that WIN lowered ADP-stimulated mitochondrial respiration in WT but not in
8 CB₁-KO mice (**Figure 2L and S2I**), indicating a specific CB₁-mediated control of
9 mitochondrial activity. Notably, this effect was also abolished in SN
10 homogenates from DN22-CB₁-KI mice, showing its dependency on mtCB₁
11 receptors (**Figure 2L and S2I**). The DN22-CB₁-KI mutant strain was viable,
12 fertile and presented normal body weight, muscular strength and locomotion
13 (**Figure S3A and S3B**). Interestingly, DN22-CB₁-KI mice did not display any
14 alteration in voluntary running wheel activity (**Figure S3C**), where global CB₁-
15 KO mice are impaired (Dubreucq et al., 2010), showing that certain CB₁
16 receptor-dependent behavioral functions are maintained in these mutants.
17 Previous evidence suggests that mtCB₁ receptors might be partly responsible
18 for electrophysiological depolarization-induced suppression of inhibition in the
19 hippocampus (DSI; Benard et al., 2012), which is known to depend on
20 endocannabinoid signaling (Wilson et al., 2001). Interestingly, DN22-CB₁-KI
21 mice displayed DSI, but its amplitude was slightly decreased as compared to
22 WT littermates (**Figure S3D and S3E**), confirming the participation of mtCB₁
23 receptors in this form of synaptic plasticity (Benard et al., 2012). Altogether,
24 these observations indicate that the constitutive deletion of the first 22 amino

acids of the CB₁ protein specifically impacts the effects of cannabinoids involving mitochondrial activity, but leave other functions of CB₁ receptors unchanged. Therefore, DN22-CB₁-KI mutant mice represent a novel and suitable tool to untangle the roles of mtCB₁ receptors.

Activation of mtCB₁ receptors decreases synaptic transmission at striatonigral terminals and induces catalepsy, but not antinociception

To explore if mtCB₁ receptors participate in the well-known cannabinoid control of synaptic transmission in the SNr (Sales-Carbonell et al., 2013; Szabo et al., 2000), we performed optogenetic-coupled electrophysiological recordings of striatonigral neurotransmission in slices. The rAAV expressing channelrhodopsin (Chr2) under the neuronal synapsin promoter (AAV-synP-Chr2-mCherry) was injected into the dorsal striatum (**Figure 3A**) of DN22-CB₁-KI, CB₁-KO mice and WT littermates. Non-dopaminergic neurons receiving Chr2-expressing fibers from striatonigral projecting neurons were recorded using whole-cell patch clamp in SNr slices (**Figure 3B**). Delivery of brief light-pulses on striatonigral terminals triggered reliable optically-induced inhibitory post-synaptic currents (oIPSCs) in SNr neurons, which were sensitive to GABA_A blockade (**Figure 3C**). Treatment with WIN (5 μM) reduced oIPSCs in WT but not in CB₁-KO mice (**Figure 3D and 3E**), suggesting a CB₁-dependent mechanism. Interestingly, WIN-mediated reduction of oIPSCs was absent in slices from DN22-CB₁-KI mice (**Figure 3D and 3E**). Furthermore, no changes

1 were observed in the paired-pulse ratio during baseline, indicating a normal
2 synaptic efficiency in DN22- CB_1 -KI mice as compared to their WT littermates
3 (**Figure S3F**). These data indicate that mt CB_1 receptors are necessary for the
4 cannabinoid-induced inhibition of synaptic transmission in the striatonigral
5 pathway, which has been proposed as a potential mechanism for cannabinoid-
6 induced catalepsy (Garcia et al., 2016). Accordingly, THC or WIN
7 administrations induced strong catalepsy in WT mice, but not in DN22- CB_1 -KI
8 littermates (**Figure 3F**). Conversely, both genotypes displayed normal
9 cannabinoid-induced antinociception (**Figure 3G**). Interestingly, WIN application
10 reduced Substance-P release in DN22- CB_1 -KI SNr slices (**Figure S3G**) to a
11 similar extent as observed in WT slices (**Figure 1K**). Furthermore, both intra-
12 SNr hemopressin infusion (**Figure S3H**), as well as systemic administration of
13 the NK_1 receptor agonist GR73632 (**Figure S3I**) strongly reduced THC-induced
14 antinociception in DN22- CB_1 -KI mice. Therefore, the CB_1 -dependent control of
15 Substance-P release in the SNr, and subsequent antinociceptive effect, do not
16 require mt CB_1 receptors. These data show that the activation of mt CB_1
17 receptors is necessary for cannabinoid-induced synaptic depression in the SNr
18 and catalepsy. Conversely, mt CB_1 receptors are dispensable for the local
19 cannabinoid-induced signaling leading to antinociception. Thus, a mechanistic
20 double dissociation of these effects of cannabinoids seems to exist in the SNr.

Cannabinoid-induced catalepsy relies on activation of striatonigral mtCB₁ receptors and mitochondrial inhibition

Striatal dopamine receptor type-1 (D₁)-positive cells are one of the major components of striatonigral circuits (Freeze et al., 2013). Notably, mice lacking the CB₁ gene in D₁-positive cells (D₁-CB₁-KO) do not display cannabinoid-induced catalepsy (Monory et al., 2007). We took advantage of this phenotype to investigate the specific impact of striatonigral mtCB₁ receptor activation on the cataleptic effect of cannabinoids. For this purpose, we adopted a CB₁ rescue approach (**Figure 4A**) by injecting Cre-dependent viral vectors expressing CB₁ or DN22-CB₁ (AAV-DIO-CB₁ or AAV-DIO-DN22-CB₁, respectively) directly into the dorsal striatum of D₁-CB₁-KO mice (expressing Cre specifically in D₁ positive cells) to specifically target striatonigral neurons (**Figure 4B and 4C**). Oxygen consumption assays revealed that WIN failed to decrease mitochondrial respiration in SN extracts from D₁-CB₁-KO mice injected with a control virus (**Figure 4D**). The re-expression of CB₁ receptors in striatal D₁-positive cells of mutant mice fully rescued the cannabinoid-induced decrease of oxygen consumption in the SN (**Figure 4D**), whereas the injection of AAV-DIO-DN22-CB₁ was not able to restore this effect (**Figure 4D**). The rescue of CB₁ receptors in striatonigral cells was sufficient to restore the cataleptic effect of THC in D₁-CB₁-KO mice (**Figure 4E**). In contrast, no catalepsy was observed after DN22-CB₁ expression in THC-treated D₁-CB₁-KO mice (**Figure 4E**). Additionally, we performed correlation analysis between the levels of CB₁ expression (**Figure 4C**) and THC-induced catalepsy (**Figure 4E**) in mice with rescue of CB₁ or DN22-CB₁. The absence of positive correlation

(**Figure S3J**) between the parameters, indicates that the subcellular localization rather than the expression levels of CB₁ determines the cataleptic effect of cannabinoids.

Thus, mtCB₁ receptor signaling in the striatonigral circuit is responsible for the local reduction of mitochondrial respiration and the cataleptic effect induced by cannabinoids.

Cannabinoid-induced catalepsy involves striatonigral mitochondrial sAC activity

To identify the molecular machinery linking the effects of cannabinoids on SN mitochondrial respiration and catalepsy, we aimed at dissecting the intramitochondrial signaling pathways involved. Stimulation of mtCB₁ receptors activates intra-mitochondrial G α_i proteins, thereby inhibiting soluble adenylyl cyclase (sAC) and protein kinase-A (PKA) activities (Hebert-Chatelain et al., 2016). The cannabinoid-induced reduction of mitochondrial respiration in SN extracts was abolished by pretreatment with the sAC inhibitor KH7 (**Figure 4F**), suggesting that sAC activity is involved in mtCB₁ receptor-dependent effects in this brain region. On the other hand, pre-treatment with the NK₁R agonist GR73632 did not impact the effect of WIN on SN respiration (**Figure S3K**), suggesting dissociation between the two pathways. To investigate whether the intra-mitochondrial sAC pathway participates in the SNr-dependent behavioral effects of THC, we first locally injected KH7 before systemic THC treatment. The sAC inhibitor blocked the cataleptic effect of THC (**Figure 4G**), without

1 impacting the behavior of mice in the hot-plate test (**Figure 4H**). Thus, similarly
2 to the impact on mitochondrial respiration, the cataleptic effect of THC requires
3 sAC activity in the SNr. However, these results do not show that the CB₁
4 signaling involved in catalepsy is specific of striatonigral neurons. Since sAC
5 expression is not limited to mitochondria and KH7 can have additional targets
6 (Valsecchi et al., 2014), pharmacological experiments cannot provide definitive
7 information about the subcellular location and the molecular specificity of the
8 observed effects. To address these issues, we used a Cre-dependent viral
9 approach to overexpress a mitochondrial-targeted version of sAC (mt-sAC-HA;
10 Hebert-Chatelain et al., 2016; Valsecchi et al., 2014) that was previously
11 reported to be targeted to mitochondria (**Figure S3L**, Pearson's coefficient
12 0.70 ± 0.04 ; Hebert-Chatelain et al., 2016) and block respiratory effects of
13 cannabinoids in cell cultures (Hebert-Chatelain et al., 2016). Striatonigral
14 overexpression of mt-sAC obtained by injecting AAV-DIO-mt-sAC-HA into the
15 dorsal striatum of D₁-Cre mice (Lemberger et al., 2007) (**Figure S3M and N**)
16 fully blocked the cannabinoid effect on mitochondrial respiration in SN extracts
17 (**Figure 4I and S3O**). Strikingly, these mice did not present any cataleptic effect
18 upon THC administration as compared to control mice (**Figure 4J**), whereas
19 they displayed a normal THC-induced antinociception (**Figure 4K**). These data
20 show that inhibition of intra-mitochondrial sAC signaling in striatonigral terminals
21 is not involved in antinociception, but it underlies the cannabinoid-induced
22 decrease of mitochondrial respiration and the subsequent cataleptic effect.

23

PKA signaling mediates both cannabinoid-induced catalepsy and antinociception, but in different subcellular compartments

Adenylyl cyclase activity triggers several signaling pathways and the activation of PKA is one of the most prominent (Dwivedi and Pandey, 2008). Inhibition of PKA is one of the best characterized signaling mechanisms of CB₁ receptor activation throughout the brain (Ibsen et al., 2017), including in striatal neurons (Borgkvist and Fisone, 2007; Martinez et al., 2012). For instance, the activity of this kinase is necessary for the stimulation of Substance-P release in spinal cord and cultured dorsal root ganglion neurons, and this mechanism is modulated by CB₁ receptors (Chen et al., 2018; Oshita et al., 2005). Within mitochondria, PKA signaling following mt-sAC activation is a target for mtCB₁-induced reduction of mitochondrial functions (Hebert-Chatelain et al., 2016). Thus, PKA inhibition at different subcellular locations might mediate pmCB₁-dependent antinociception and mtCB₁-dependent catalepsy, by reducing Substance-P release and inhibiting mitochondrial respiration, respectively. To test this hypothesis, we used constructs expressing constitutively active mutant forms of PKA (Niswender et al., 2005) targeted either to the cytosol (PKA-CA, myc tagged) or to the mitochondria (MLS-PKA-CA, myc-tagged, **Figure S3P**; Hebert-Chatelain et al., 2016). These constructs were used to generate rAAVs for Cre-dependent expression, which were injected into the dorsal striatum of D₁-Cre mice. By this way, we obtained expression of these two different forms of constitutively active PKA in striatonigral neurons (**Figure S3Q**). Expression of PKA-CA did not alter catalepsy, but it blocked the antinociceptive effect of THC (**Figure 4L and 4M**). Conversely, the expression of MLS-PKA-CA dampened

the cataleptic effect of THC, without changing the antinociception (**Figure 4L and 4M**). Importantly, the expression of PKA-CA did not alter cannabinoid-induced decrease of mitochondrial respiration in SN extracts, whereas MLS-PKA-CA abolished this effect (**Figure 4N and S3R**). These data show that inhibition of PKA activity in striatonigral neurons mediates both cataleptic and antinociceptive effects of cannabinoids. However, the specific subcellular location of the activity of this kinase is differentially involved in these effects. Whereas intra-mitochondrial sAC-PKA signaling mediates cannabinoid-induced decrease of mitochondrial respiration and catalepsy, the antinociceptive effect of these drugs relies on the inhibition of cytoplasmic PKA.

DISCUSSION

This study reveals that the differential subcellular localization of a receptor can bias the behavioral consequences of its activation in the same brain circuit. *Via* the regulation of specific subcellular molecular pathways, striatonigral neurons are the substrate of both adverse cataleptic and clinically-relevant antinociceptive effects of cannabinoids. While stimulation of pmCB₁ receptors at striatonigral terminals induces inhibition of nociceptive responses, presynaptic mtCB₁ receptors in the same location are responsible for cataleptic effects of cannabinoids (**Figure S4**). Mechanistically, cannabinoid-induced catalepsy relies on mtCB₁ receptor-dependent regulation of intramitochondrial sAC/PKA signaling, inhibition of mitochondrial respiration and decrease of inhibitory synaptic transmission at striatonigral terminals. Conversely, antinociception requires pmCB₁ receptor-dependent reduction of cytosolic PKA activity and decrease of Substance-P/NK₁ receptor signaling (**Figure S4**).

1 The SNr, being a key part of the basal ganglia loop (Freeze et al., 2013), is
2 classically considered to provide mainly motor regulation, integrating striatal
3 pathways and regulating the activity of motor cortex through thalamic
4 projections (Borsook et al., 2010). However, the SNr also, directly and indirectly,
5 modulates the activity of several brain regions involved in pain processing such
6 as the superior and inferior colliculus, pedunculo pontine nucleus (PPN), rostral
7 ventral medulla and dorsal root ganglia (Borsook et al., 2010; Zhou, 2016).
8 Moreover, several electrical and optogenetic stimulation studies revealed a
9 novel nociceptive network, e.g Subthalamic Nucleus – SNr – superior colliculus
10 and parabrachial nucleus (Luan et al., 2020; Pautrat et al., 2018). Thus, the SNr
11 is ideally placed to control voluntary movement, as well as nociceptive
12 responses. There could be two different sets of striatonigral neurons, one
13 dedicated to nociception control (as indicated by the presence of different
14 nociceptive neurons in the SNr and the other to movement control (as already
15 extensively studied (Borsook et al., 2010). Alternatively the same neurons could
16 be involved in both effects according to the different inputs received and
17 possibly differential molecular mechanisms triggered by those inputs (Chudler
18 and Dong, 1995). In this scenario, the subcellular localization of CB₁ receptors
19 could serve as a molecular switch regulating motor control and pain perception.

20 More recently, an emerging idea started to grow in brain research about the
21 possibility that specific subcellular locations of a molecular process could trigger
22 different cellular effects (Creighton, 2011; Ilouz et al., 2017). For instance,
23 although their relative impact on behavior has not been investigated so far,
24 specific subcellular locations of targeted molecules have been proposed to

1 differentially modulate cellular processes in the same brain cells (Bucko et al.,
2 2019; Qi et al., 2019; Skälhegg and Tasken, 2000). The recent evidence that
3 certain GPCRs, including CB₁, can functionally localize to different organelles
4 (Benard et al., 2012; Eichel and von Zastrow, 2018; Hebert-Chatelain et al.,
5 2016; Lahuna and Jockers, 2018) indicates that they might be directly involved
6 in these subcellular-specific signaling pathways and their behavioral
7 consequences. Moreover, given the crucial role of proper GPCRs trafficking
8 for their activity (Lobingier and von Zastrow, 2019), one might speculate that
9 a transient mitochondrial passage might be a determinant of certain CB₁
10 functions at plasma membranes. Although not yet possible to be directly
11 addressed experimentally, this interesting hypothesis might change the current
12 view of receptor trafficking and will be for sure the subject of future studies.

13 The activation of mtCB₁ receptors in striatonigral terminals is responsible for the
14 effects of cannabinoids on cellular respiration, synaptic transmission and
15 behavioral catalepsy. A growing body of evidence highlights the importance
16 of mitochondrial functions for the regulation of synaptic transmission (Garcia
17 et al., 2019; Vos et al., 2010), but little is known concerning the detailed
18 molecular mechanisms linking the organelle to the synaptic machinery. The
19 constant supply of ATP produced by mitochondria is considered to be a key
20 element for sustaining synaptic transmission (Rangaraju et al., 2014). By
21 regulating mitochondrial respiration at synaptic terminals, mtCB₁ receptors
22 are therefore perfectly placed to potentially dampen inhibitory striatonigral
23 neurotransmission and, thereby, induce catalepsy upon pharmacological
24 activation. This suggests that similar mechanisms might occur during

1 physiological fine-tuned control of movements, thereby establishing a link
2 between mitochondrial activity, synaptic transmission and motor control.

3 The assessment of nociception in animal models necessarily relies on the
4 observation of motor responses. Thus, it has been proposed that cannabinoid-
5 induced decrease of pain reactions might be secondary to motor impairments,
6 such as catalepsy, rather than reflecting proper antinociception (Giuffrida and
7 Seillier, 2012; Pertwee, 2001). However, analgesic and antinociceptive effects
8 of cannabinoids have been observed at several supraspinal and spinal
9 locations, in the absence of motor alterations, indicating that these two effects
10 can be discriminated at the level of different brain and spinal cord regions
11 (Woodhams et al., 2017). Our data show that both behavioral outputs can be
12 mediated by activation of CB₁ receptors located in different subcellular
13 organelles in striatonigral neurons, triggering distinct molecular mechanisms.
14 This does not only add a new location for cannabinoid effects, but it also shows
15 that CB₁ receptor-dependent catalepsy and antinociception rely on a true
16 intracellular mechanistic dichotomy, likely involved in the physiological
17 regulation of complex processes, such as motor and pain control. This
18 dichotomy, observed after acute pharmacological activation of CB₁ receptor,
19 might be also underlying the physiological role of endogenous cannabinoids in
20 motor regulation and pain processing. Indeed, pharmacological and/or genetic
21 CB₁ receptor blockade increases the sensitivity to pain perception (Clapper et
22 al., 2010; Nadal et al., 2013) and also have been often reported to increase
23 locomotor reactivity (Griebel et al., 2005; Häring et al., 2011). On the other
24 hand, like THC and other cannabinoid agonists, inhibitors of endocannabinoids

1 degradation are able to induce antinociception and catalepsy via CB₁ receptor
2 activation (Long et al., 2009), further confirming the endogenous role of the
3 receptor in regulating these two physiological processes.

4 Cannabinoids induce antinociception through the pmCB₁ receptor-dependent
5 reduction of Substance-P release in striatonigral neurons and the consequent
6 decrease of local NK₁ receptor signaling. Interestingly, Substance-P in the SNr
7 participates in pain processing, possibly through the modulation of the activity of
8 rostral ventral medulla and dorsal root ganglia(Boccella et al., 2020; Borsook et
9 al., 2010; Taylor et al., 2016). Therefore, the CB₁ receptor-dependent
10 modulation of Substance-P/NK₁ signaling in the striatonigral neurons is a novel
11 mechanism that likely participates in larger circuits modulating nociceptive
12 responses.

13 To conclude, CB₁ receptors in the striatonigral circuit mediate cannabinoid-
14 induced catalepsy and antinociception. This regulation clearly involves distinct
15 subcellular and molecular mechanisms in the same neuronal circuit, resulting in
16 the respective control of neurotransmitter and neuropeptide release. Thus,
17 selective subcellular manipulations of CB₁ receptors represent a potential
18 therapeutic strategy to avoid undesirable effects of cannabinoid drugs, and to
19 promote their beneficial pain treatment. The unforeseen dichotomy between
20 cannabinoid-induced mitochondrial catalepsy and non-mitochondrial
21 antinociception in the same cellular population introduces the concept of
22 subcellular specificity of behavioral control.

1 **ACKNOWLEDGMENTS**

2 We thank Delphine Gonzales, Nathalie Aubailly, and all the personnel of the
3 Animal Facility of the NeuroCentre Magendie for mouse care. We also thank all
4 the members of the Marsicano lab for useful discussions, Virginie Morales for
5 invaluable help with administrative work. We thank the Histology and
6 Biochemistry platforms of the NeuroCentre Magendie, as well as the Bordeaux
7 Imaging Center (BIC) for help in the experiments. We thank G. Manfredi
8 (Cornell University) for the mt-sAC-HA. We thank Su Melser for helpful
9 suggestions regarding the mitochondrial respiration and Roman Serrat for help
10 in imaging. We also thank Daniela Cota, Manuel Guzman, Pavel E. Rueda-
11 Orozco, and Guillaume Ferreira for their useful and critical reading on the
12 manuscript. This work was supported by INSERM (to G.M. and L.B.), EU-FP7
13 (PAINCAGE, HEALTH-603191 to G.M.), European Research Council
14 (Endofood, ERC-2010-StG-260515; CannaPreg, ERC-2014-PoC-640923,
15 Micabra to G.M.), Fondation pour la Recherche Medicale (DRM20101220445 to
16 G.M. and ARF20140129235 to L.B.). Human Frontiers Science Program (to
17 G.M.), Region Aquitaine (to G.M.), French State/Agence Nationale de la
18 Recherche (LABEX BRAIN ANR-10-LABX-43 to G.M., JCJC MitoCB1-fat to
19 L.B.), Marie Skłodowska-Curie Actions Individual Fellowships (H2020-MSCA-IF-
20 2016, ID747487 to C.M.), the Basque Government (IT1211/19 to L.F.C.),
21 Fyssen Foundation, CONACyT, Ikerbasque and MINECO (Ministerio de
22 Economía y Competitividad) PGC2018-093990-A-I00 (MICIU/AEI/FEDER, UE)
23 (to E.S.-G.). NSERC Discovery Grant - RGPIN-2019-06274 (to A.W.H. and
24 R.F.). The Basque Government (IT1230-19 to P.G.), Red de Trastornos

Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU; RD16/0017/0012 to P.G.), MINECO/FEDER, UE (SAF2015-65034-R to P.G.) and MINECO/FEDER, UE (POP contract BES-2016-076766 to I.B.-D.R.

AUTHOR CONTRIBUTIONS

E.S-G., and L.B., performed and analyzed behavioral, biochemical and anatomical experiments. A.C.P.Z., C.M., M.L.B-J., R.F., I.M.M., Y.O.A., A.C., T.L-L., P.V., T.T-C., J.S.B., E.H-C., G.B-G., A.W.L., and L.F.C. performed and analyzed biochemical experiments. Y.M., T.D., L.M.R., J.F.C.O., S.C., J.C., L.M., B.R., A.B-G., and F.C., performed and analyzed behavioral experiments. M.B., G.T., and J.B., performed and analyzed electrophysiological experiments. Y.M., I.B-d-R., M.V., Z.Z., F.J-K., N.P., and P.G., performed and analyzed anatomical experiments. E.S-G., G.M., and L.B., conceived and supervised the whole project and wrote the manuscript. All authors edited and approved the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

STAR METHODS

Animals

Experiments were approved by the Committee on Animal Health and Care of INSERM, and the French Ministry of Agriculture and Forestry (authorization number 3306369). Mice were maintained under standard conditions (food and water *ad libitum*; 12h/12h light/dark cycle, light on 7 a.m.; experiments were performed between 9 a.m. and 5 p.m.). C57BL/6-N male mice (2–4 months old) were purchased from Janvier (France). D₁-CB₁-KO mice and their WTs littermates were generated and maintained as previously described (Monory et al., 2007). D₁-Cre mice (Lemberger et al., 2007) were kindly provided by Günther Schütz, (German Cancer Research Center). DN22-CB₁-KI mice were generated using a flox-stop strategy as previously described (Ruehle et al., 2013). Stop cassette was excised *via* a Cre deleter mouse strain and knock-in mice were maintained over a C57BL6/N background for several generations before experiments.

Drugs

THC was obtained from THC Pharm GmbH (Frankfurt, Germany). AM251, Hemopressin and GR73632 were purchased from Tocris (France). WIN 55,212-2 mesylate salt and KH7 were obtained from Sigma Aldrich (France). THC (10mg/kg) was dissolved in a mixture of saline (0.9% NaCl) with 5% ethanol and 4% cremophor. WIN 55,212-2 was dissolved in DMSO for *in vitro* experiments and in mixture of DMSO, Tween80 (1.25-1.25-97.5) and saline for *in vivo* treatments. Hemopressin (22 ng in 0.5 µl) and GR73632 (100ng in 0.5µl) were dissolved in saline. AM251 (4 µg in 0.5µl) and KH7 (2µg in 0.5µl) were

dissolved in 10% DMSO, 10% cremophor and 80% saline. Vehicles contained the same amounts of solvents respectively to the drug. All drugs were prepared fresh before the experiments.

Viral vectors

To generate AAV-DIO-CB₁, AAV-DIO-DN22, AAV-DIO-mt-sAC-HA, AAV-DIO-PKA-CA and AAV-DIO-MLS-PKA-CA the coding sequences for the 5 proteins(Hebert-Chatelain et al., 2016) were subcloned in pAAV-CAG-flex plasmid (kindly gifted by Matthias Klugmann, UNSW, Australia) by using standard molecular cloning techniques. The same pAAV-CAG-flex plasmid was used as empty control (AAV-DIO-ctr). AAVs were generated by PEI transfection of HEK 293T cells and purified by iodixanol-gradient ultracentrifugation as previously described(Hebert-Chatelain et al., 2016). Virus titers were 5.43×10^{11} for AAV-DIO-CB₁, 3.34×10^{11} for AAV-DIO-DN22, 2.36×10^{11} for AAV-DIO-mt-sAC-HA, 3.87×10^{11} for AAV-DIO-PKA-CA, 3.96×10^{11} for AAV-DIO-MLS-PKA-CA and 4.51×10^{11} for AAV-DIO-ctr, expressed as genomic copies (GC) x ml.

For optogenetic experiments, rAAV2-hSyn-ChR2(H134R)-mCherry (10^{13} GCxml) and rAAV-hSyn-DIO-ChrimsonR-tdTomato (5.2×10^{12} GCxml) were purchased from UNC vector core (USA) and Viral Vector Facility (VVF) of the Neuroscience Center Zurich (Zentrum für Neurowissenschaften Zürich, ZNZ) respectively.

The viral vectors used for CB₁ deletion experiment (see *next section*) were purchased from the VVF. Titres were: 6.4×10^{12} for AAV-retro-hSyn1-EBFP2-FLPo, 4.1×10^{12} for AAV-retro-hSyn1-EBFP2 and 6.3×10^{12} for AAV-hEF1a-dFRT-iCre-EGFP.

Surgery and drug/virus administration

For intra-SNr injections of drugs mice were anesthetized by intraperitoneal injection of a mixture of ketamine (100mg/kg, Imalgene 500®, Merial) and Xylazine (10mg/kg, Rompun, Bayer) and placed into a stereotaxic apparatus (David Kopf Instruments) with mouse adapter and lateral ear bars. Mice were allowed to recover for at least one week in individual cages before the beginning of the experiments. Mice were weighed daily and individuals that failed to regain the pre-surgery body weight were excluded from the following experiments. Mice were bilaterally implanted with 3.5 mm stainless steel guide cannulae (Plastics One, USA) targeting the SNr with the following coordinates: AP -3.2, L $\pm$ 1.3, DV -3.5, according to Paxinos and Franklin (Paxinos and Franklin, 2001). Guide cannulae were secured with cement anchored to the skull by screws. The drug injections for intra-SNr were performed by using injectors protruding 1 mm from the tip of the cannula. The correct placement of the SNr cannulas was verified by injection of sky-blue toluidine followed by neutral red staining (Soria-Gomez et al., 2014) (**Figure S1A**).

AAV injections of AAV-DIO-CB₁ or AAV-DIO-DN22 in the dorsal striatum of D₁-CB₁-KO mice, or AAV-DIO-mt-sAC-HA, AAV-DIO-PKA-CA and AAV-DIO-MLS-PKA-CA in D₁-Cre mice, with respective AAV-DIO-Ctr, were performed with the following coordinates: AP +0.5, L $\pm$ 2.0, DV -3.0 as previously described (Bellocchio et al., 2016).

For the specific deletion of CB1 in the striatopallidal or striatonigral neurons, mice were anesthetized by inhalation of isofluorane 5% and placed into the stereotaxic apparatus with the anesthesia maintained at 2% during the entire

surgery. AAV vectors were injected with the help of a microinjector (Nanoject III, Drummond Scientific, PA, USA). The deletion was performed injecting the viral vectors AAV-hEF1a-dFRT-iCre-EGFP in the dorsal striatum, STR (2 injections of 1µl per side) with the following coordinates: AP + 0,8 ML $\pm$ 2,0 DV -3,0 and -3,5; and the retrograde vector AAV-retro-hSyn1-EBFP2-FLPo or AAV-retro-hSyn1-EBFP2 as control in one of its target external Globus Pallidus, GPe or Substantia nigra pars reticulata, SNr (respectively AP – 0,5 ML $\pm$ 1,8 DV – 4,25; volume 350 nl per side and AP – 3,25 ML $\pm$ 1,35 DV – 4,5; volume 750 nl per side).

Animals were allowed to recover for at least four weeks before the beginning of biochemical (see after) or behavioral experiments. Mice that underwent behavioral experiments were fixed by transcardial perfusion of 4% PFA and their brain were processed for imaging (to detect BFLP and EGFP) and double fluorescent in-situ hybridization (see below), or for immunofluorescence as previously described (Hebert-Chatelain et al., 2016), with primary antibodies directed against CB₁ receptor (CB₁-Go-Af450-1; 2 µg/ml; Frontier Science Co. Ltd), to detect CB₁ rescue and CB₁ deletion, or against HA-tag (#3724; Cell Signaling Technology Danvers, MA) to confirm overexpression of mt-sAC. Mice that did not fulfill histological positive criteria were excluded from the study.

Double fluorescent in-situ hybridization coupled to GFP immunodetection

Double FISH/GFP immunofluorescence experiments to measure the number of CB₁/D₁R vs CB₁/D₂R positive striatal neurons in the deletion experiments, were carried out as previously described (Oliveira da Cruz et al., 2020; Terral et al., 2019). Briefly, free-floating frozen coronal sections were cut out with a cryostat

(30 μ m, Microm HM 500M Microm Microtech) and collected in an antifreeze solution and conserved at -20°C . After inactivation of endogenous peroxidases and blocking with Avidin/Biotin Blocking Kit (Vector Labs, USA), sections were processed with a combination of FITCH coupled riboprobe against mouse CB₁ receptor (1:1000, prepared as described in Marsicano and Lutz, 1999) together with Digoxigenin (DIG)-labeled riboprobe against D1R or D2R (1:1000 Monory et al., 2007). Signals were revealed with a TSA reaction using fluorescein isothiocyanate (FITC)-labeled tyramide (1:80 for 12 minutes, Perkin Elmer) for CB₁ receptor, or with Streptavidin-Texas Red (1:400, PerkinElmer) for D1R or D2R receptor. Sense control probes were used to establish background signal. After processing for FISH, anti-GFP immunofluorescence was carried out as previously described (Oliveira da Cruz et al., 2020; Terral et al., 2019). Counting of co-expressing cells was performed manually over 20x objective fluorescent microscope as previously described (Bellocchio et al., 2010, Oliveira da Cruz et al., 2020; Terral et al., 2019). Image analyses and counting was performed in at least 6 striatal slice per mouse averaging results from 3-4 mice. This resulted in counting 1300-1600 neurons in average per each condition/analysis.

Quantitative real-time PCR (qRT-PCR).

Samples from WT, DN22-CB₁-KI and CB₁-KO mice were homogenized in Tri-reagent (Euromedex, France) and RNA was isolated using a standard chloroform/isopropanol protocol (Chomczynski and Sacchi, 1987). RNA was processed and analyzed following an adaptation of published methods. cDNA was synthesized from 1 μ g of total RNA using Maxima Reverse Transcriptase (Thermo Scientific, USA) and primed with oligo-dT primers (Thermo Scientific,

USA) and random primers (Thermo Scientific, USA). qRT-PCR was performed using a LightCycler® 480 Real-Time PCR System (Roche, Switzerland). qRT-PCR reactions were done in duplicate for each sample, using transcript-specific primers, cDNA (4 ng) and LightCycler 480 SYBR Green I Master (Roche, Switzerland) in a final volume of 10 µl. The PCR data were exported and analyzed in an informatics tool (Gene Expression Analysis Software Environment) developed at the NeuroCentre Magendie. For the determination of the reference gene, the Genorm method was used (Livak and Schmittgen, 2001). Relative expression analysis was corrected for PCR efficiency and normalized against two reference genes. Valosin containing protein (Vcp) and succinate dehydrogenase complex subunit (Sdha) genes were used as reference genes for Amygdala. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and Sdha genes were used as reference genes for Hippocampus. Tubulin alpha 4 a (Tuba4a) and tyrosine 3 mono oxygenase tryptophan 5 mono oxygenase activation protein zeta (Ywhaz) genes were used as reference genes for Anterior Olfactory Nucleus. Sdha and tubulin alpha 4 a (Tuba4a) genes were used as reference genes for Prefrontal Cortex. Actin, beta (Actb) and tTubulin alpha 4 a (Tuba4a) genes were used as reference genes for STR. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and peptidylprolyl isomerase A (Ppia) genes were used as reference genes for Hypothalamus. The relative level of expression was calculated using the comparative ($2^{-\Delta CT}$) method (Livak and Schmittgen, 2001). Primers sequences are reported in the following table:

Gene	GenBank ID	Forward Sequence (5'-3')	Reverse Sequence (5'-3')
Vcp	NM_009503	TGGCCGTCTAGATCAGCTCAT	TTTCGCAGATTGGCTTTTAGG
Sdha	NM_023281	TACAAAGTGCGGGTCGATGA	TGTTCCCCAAACGGCTTCT
Gapdh	NM_008084	TCAAGAAGGTGGTGAAGCAG	TGGGAGTTGCTGTTGAAGTC
Tuba4a	NM_009447	CCACTTCCCCTTGGCTACCTA	CCACTGACAGCTGCTCATGGT
Ywhaz	NM_011740	CTTGTGAGGCTGTGACACAAAC	CAAGAGTGTGCACGCAGACA
Actb	NM_007393	TGACCGAGCGTGGCTACA	CATAGCACAGCTTCTCTTTGATGTC
Ppia	NM_008907	CAAATGCTGGACCAAACACAA	GCCATCCAGCCATTTCAGTCT
Cnr1	NM_007726	GTCGATCTTAGACGGCCTTGC	TTGAGCCCACGTAGAGGAGGT
Cnr1	NM_007726	GTGCTGTTGCTGTTTCATTGTG	CTTGCCATCTTCTGAGGTGTG

1

2 Mitochondrial respiration

3 Mitochondrial respiration in substantia nigra extracts was measured as
4 previously described(Hebert-Chatelain et al., 2016) with some modification.
5 Briefly, immediately after cervical dislocation, the mouse brain was extracted
6 and the substantia nigra was rapidly dissected using the coronal brain
7 matrix(Vallee et al., 2014) and was homogenized in 450 µl of Miro5 buffer
8 without taurine supplementation (Makrecka-Kuka et al., 2015) using a Politron
9 homogenizer (11.000 rpm 3-5 sec). After brief centrifugation the supernatant
10 was treated with saponin at a final concentration of 12.5 µg/ml. Respiration
11 analyses were carried out using a 2K Oroboros device(Makrecka-Kuka et al.,
12 2015). 100 µl of lysate were put in each chamber and complex I-dependent

respiration was triggered by adding malate (2mM), pyruvate (5mM) and glutamate (10 mM) (MPG)(Makrecka-Kuka et al., 2015). Then we applied DMSO or WIN 55,212-2 at final concentration of 1 μ M and 5 minutes after we injected 1.25 mM ADP. Each measure of OCR in ADP condition was normalized to the values before ADP injection and the effect of WIN 55,212-2 was expressed as percentage of vehicle conditions. Only samples for which the ratio of ADP/MPG in the vehicle was equal or superior to 1.5 were retained for the analyses. In the experiments of KH7 pre-treatment, the drug was dissolved in DMSO (used as vehicle) and injected together with the lysates at a final concentration of 5 μ M.

In a previous set of experiments we validated the quality of mitochondria in the preparation by measuring the O₂ consumption after the MPG and ADP administration. We added the complex II substrate Succinate at the final concentration of 10mM, 10 μ M Cytochrome C, to check mitochondrial membrane integrity, and finally Rotenone (0.5 μ M) and Antimycin A (2.5 μ M) inhibitors of complex I and III, respectively(Makrecka-Kuka et al., 2015) (**Table S1**). When using homogenates from virus-injected mice (see above) 40ul of samples were processed for western blotting against sAC, HA-tag and myc-tag to confirm overexpression of mt-sAC and the different forms of PKA-CA in the SNr of D₁-Cre mice respectively.

Mitochondrial isolation from mouse striatum

In this set of experiments, D₁-Cre mice were injected with control AAV vector, AAV-DIO-mt-sAC-HA, AAV-DIO-PKA-CA and AAV-DIO-MLS-PKA-CA as described above. Mice were sacrificed by cervical dislocation, brains were

rapidly extracted and the striatum dissected on ice. Mitochondria were extracted by immuno-magnetic isolation using the Mitochondrial Extraction and Isolation Kits (Milteny Biotech, FRANCE) according to manufacturer instructions. After tissue lysis in 1.5ml of protease inhibition buffer provided by the manufacturer, one small fraction was collected as total cell lysate (TCL). Extracted mitochondria and their respective TCL were re-suspended in the same buffer, quantified for their protein content and loaded on polyacrylamide gel (12µg per sample) for western blotting as described below.

Western Blotting

Protein homogenates in Miro5, added with protease inhibitors (Complete protease inhibitor cocktail, Sigma-Aldrich, France) have been mixed with denaturing 4x Laemmli loading buffer (250 mM Tris-HCl, 40% Glycerol, 8% SDS, 5% β-Mercaptoethanol, 0.2% Bromophenol blue) and boiled at 95°C for 5 minutes. Samples were analyzed on 4-20% precast polyacrylamide gels (Bio-Rad, Hercules, California) and transferred onto PVDF membranes 0.45µm (Merk Millipore, Burlington, MA). Membranes were blocked in a mixture of Tris-buffered saline and polysorbate 20 (20mM Tris-HCl pH 7.6, 150mM NaCl, 0.05% Tween 20) containing 5% of non-fat dry milk for 1 h at room temperature. For immunoblotting have been used antibodies against HA-Tag (#3724; 1:1000, Cell Signaling Technology Danvers, MA or #PA1-985; 1:1000, Thermo Fisher Scientific, Waltham, MA), myc-tag (#11667149001; 1:500, Merk, Darmstadt, Germany), sAC (ADCY10 PA-543049; 1:1000, Thermo Fisher Scientific, Waltham, MA), TOMM20 (#sc-111415, 1:1000, Santa Cruz Biotechnology, Dallas, Texas), PKA catalytic subunit (#Ab76238, 1:2000, Abcam, Cambridge,

UK) and Tubulin (sc-69969; 1:5000, Santa Cruz Biotechnology, Dallas, Texas) .
Bound primary antibodies were detected with HRP-linked antibodies (1:2000,
Cell Signaling Technology, Danvers, MA) and visualized by enhanced
chemiluminescence detection (Clarity Western ECL Substrate, Bio-Rad,
Hercules, California or Super Signal West Femto Maximum Sensitivity
Substrate, Thermo Fisher Scientific, Waltham, MA) The images have been
acquired on ChemiDoc Touch (Bio-Rad, Hercules, California and analysed
using the Image Lab software (Bio-Rad, Hercules, California)

[³⁵S]GTPγS binding assay on brain homogenates

Brains from 8 mice of each genotype (WT, *CB₁*-KO and DN22-*CB₁*-KI) were
obtained. Midbrain, cortex and hippocampus were dissected and immediately
stored at -70 °C until assay. For each brain region, tissue samples from each
genotype were pooled to obtain the enriched fractions of plasma membranes.
Tissue samples were homogenized using an a Teflon-glass grinder (IKA
Labortechnik, Satufen, Germany) at 1500 rpm (10 up-and-down strokes) in 30
volumes of homogenization buffer (1 mM EGTA, 3 mM MgCl₂ , 1 mM DTT, and
50 mM Tris-HCl, pH 7.4) supplemented with 0.25 M sucrose. The crude
homogenate was centrifuged for 5 minutes at 1,000 x g at 4 °C and the
supernatant layer was re-centrifuged for 10 minutes at 40,000 x g (4°C). The
resultant pellet (P2 fraction) was washed twice in 10 and 5 volumes of
homogenization buffer respectively, and re-centrifuged in similar conditions.
Protein content was measured according to Bradford's method using BSA as
standard. Samples were aliquoted in order to have a protein content of 1 mg
and then centrifuged in a benchtop centrifuge (EBA 12 R, Hettich Instruments,

1 Tuttlngen, Germany) at highest speed (14,000 rpm) during 15 minutes at 4 °C.
2 The supernatant layer was carefully discarded and the pellets stored at -70 °C
3 until assay. The tissue samples of the nine experimental conditions (3
4 genotypes and 3 brain regions, 1 pool for each region-genotype) were
5 processed in parallel on the same day. The day of the experiment the
6 membrane pellets were defrosted (4°C), thawed and re-suspended in 11 ml of
7 incubation buffer containing 1 mM EGTA, 3 mM MgCl₂ , 100 mM NaCl, and 50
8 mM Tris-HCl, pH 7.4, reaching a final protein concentration of 0.09 mg/ml
9 approximately. The real final protein content was measured after the experiment
10 according to Bradford's method.

11 WIN 55,212-2 stimulated [³⁵S]GTPγS binding assays were carried out in a final
12 volume of 250 µl in 96 well plates, containing 1 mM EGTA, 3 mM MgCl₂, 100
13 mM NaCl, 0.2 mM DTT, 50 µM GDP, 50 mM Tris-HCl at pH 7.4 and 0.5 nM
14 [³⁵S]GTPγS. Stimulation curves were carried out by incubating increasing
15 concentrations of WIN 55,212-2 (10⁻¹²-10⁻⁴ M; 9 concentrations by duplicate;
16 three independent experiments). The incubation was started by addition of the
17 membrane suspension (18 µg of membrane proteins per well) and was
18 performed at 30°C for 120 minutes with shaking (450 rpm). Incubation was
19 terminated by rapid filtration under vacuum (1450 FilterMate Harvester,
20 PerkinElmer) through GF/C glass fiber filters (Printed Filtermat A) pre-soaked in
21 ice-cold incubation buffer. The filters were then rinsed three times with 300 µl
22 ice-cold incubation buffer, air dried (20°C, 120 minutes), and counted for
23 radioactivity (4 minutes) by liquid scintillation spectrometry using a MicroBeta
24 TriLux counter (PerkinElmer). Non-specific binding of the radioligand was

defined as the remaining [^{35}S]GTP γ S binding in the presence of 10 μM unlabelled GTP γ S, and the basal binding, as the signal in the absence of agonist. The pharmacological parameters of the stimulation curves of the [^{35}S]GTP γ S binding, the maximal effect (E_{max}) and the concentration of the drug that determines the half maximal effect (EC_{50}), were obtained by non-linear analysis using GraphPad PrismTM software version 5.0. The points fit to a concentration-response curve (standard slope). The pharmacological parameters E_{max} and EC_{50} are expressed as means $\pm$ SEM. The statistical comparison of the data sets was performed in GraphPad PrismTM software version 5.0, by a co-analysis of the curves.

[^{35}S]GTP γ S and [^3H]CP55,940 binding assay on brain slices

[^{35}S]GTP γ S (1250 Ci/mmol) and [^3H]CP55,940 (149 Ci/mmol) were purchased from PerkinElmer (Boston MA, USA). The [^{14}C] and [^3H] standards were supplied by American Radiolabelled Chemicals (St. Louis, MO, USA). DL-dithiothreitol (DTT), guanosine-5'-diphosphate (GDP), and guanosine-5'- γ -3-thiotriphosphate (GTP γ S) were acquired from Sigma-Aldrich (St. Louis, MO, USA). WIN 55,212-2 was purchased from Tocris Bioscience (Bristol, UK). All other chemicals were obtained from standard sources and were of the highest purity commercially available.

In order to test the ability of CB_1 receptor to stimulate GTP γ S conversion after WIN 55,212-2 administration or to bind the CP55,940 agonist, 5-6 WT and DN22- CB_1 -KI mice, and 1 CB_1 -KO mouse as control, were sacrificed by cervical dislocation and their brain rapidly frozen at -80°C . 20 μm slices were cut with a cryostat and mounted on superfrost (Thermo Scientific, FRANCE) slides.

1 [³⁵S]GTP γ S binding assay. Brain sections were thawed for 15 min and then
2 incubated in 50 mM Tris-HCl buffer with 3 mM MgCl₂, 0.2 mM EGTA, 100 mM
3 NaCl, 2 mM GDP and 1 mM DTT (pH = 7.4) for 20 min at room temperature.
4 Afterwards, the slices were incubated with 0.04 nM [³⁵S]GTP γ S in absence and
5 in presence of WIN 55,212-2 μ M (1 and 10 μ M) for 2 h at 30°C. The non-
6 specific binding was determined with 10 μ M GTP γ S. Finally, the sections were
7 washed twice in 50 mM Tris-HCl (pH = 7.4) for 15 min at 4°C, dried and exposed
8 to a Kodak Biomax MR film with ¹⁴C standards. The films were scanned and
9 quantified by transforming the optical densities into nCi/mg using the ¹⁴C
10 standards (NIH-IMAGE, Bethesda, MA, USA). The background and the non-
11 specific densities were subtracted. The percentages of stimulation were
12 calculated from the basal and agonist-stimulated [³⁵S]GTP γ S binding densities
13 according to the formula (stimulated x 100/basal) - 100.

14 [³H]CP55,940 binding assay. Tissue sections were dried and incubated in 50
15 mM Tris-HCl buffer containing 1% of BSA (pH = 7.4) for 30 min at room
16 temperature. Later, the brain sections were incubated again in the same buffer
17 supplemented with 3 nM [³H]CP55,940 for 2h at 37°C. Non-specific binding was
18 determined with 10 μ M WIN 55,212-2. Finally, sections were washed in ice-cold
19 50 mM Tris-HCl buffer supplemented with 1% BSA followed by dipping in
20 distilled water at 4°C. After drying, the brain slides were exposed to a radiation
21 sensitive film for 21 days at 4°C together with tritium standards. The films were
22 scanned and quantified by transforming the optical densities into nCi/mg using
23 the tritium standards (NIH-IMAGE, Bethesda, MA, USA). The background and
24 the non-specific densities were subtracted to determine the specific binding.

Behavioral tests

Wire hang test. Wild type and DN22-CB₁-KI mice were tested for their muscular strength in the wire hang test (Redon et al., 2020). All tests were conducted during the dark phase of the cycle under dim red light. Each cage, housing one mouse, was placed on a bench in a room adjacent to the one housing the mice. Thereafter, each mouse was removed from its cage, placed on the cage grid, the latter being then slowly inverted as to be suspended 90 cm above a big cage filled with polystyrene beads. The latency to fall was then recorded.

Basal locomotion. The basal locomotor activity of WT and DN22-CB₁-KI mice was measured during seven days using the TSE PhenoMaster system (TSE Systems GmbH). Mice were placed individually in a plexiglass cage [45cm (length) X 34cm (width) X 20cm (height)] surrounded with the ActiMot module containing IR light beams recognizing locomotor activity. Food and water were available *ad libitum*.

Catalepsy, locomotion and antinociception. AM251 and Hemopressin were bilaterally injected into the SNr in a volume of 0.5 µl per side. Immediately after, THC (10 mg/kg) was injected i.p. Mice were tested, 30 min post-injections, successively for catalepsy, locomotion and antinociception. Locomotor activity was tested by placing the mouse in a novel environment and the number of squares crossed was counted for 5 minutes. For seek of clarity, given the fact that striatonigral CB₁ receptor deletion did not affect the hypo-locomotor effects of THC (**Figure S1B and S1E**), we did not show results for this behavioral paradigm for the other experimental sets. The catalepsy was determined by the time of immobility on a bar. To this aim, mice were positioned in a new plastic

cage (identical to their home cage) without bedding with on a horizontal cylindrical bar (0.7cm Diameter) placed at 4.5 cm high with their forepaws gripping and its hind paws in the plastic box. The time spent in its initial position on the bar was scored for two minutes. Immediately after, mice were placed in a Hot Plate (BIOSEB) to measure antinociception. The plate was pre-heated at 52°. The escape latency, defined as the time until the mice showed signs of discomfort (paw licking, jumping), was recorded. All equipment was cleaned with ethanol 25% and dried with paper towels between all the trials. For AAVs injected mice the procedure was identical but mice were tested 5 weeks after viral injections.

Immuno-electron microscopy

The experiments were performed as described previously(Puente, 2019). *CB₁*-KO, DN22-*CB₁*-KI, and respective WT littermates mice (n = 3 per genotype) were deeply anesthetized by intraperitoneal injection of ketamine/xylazine (80/10 mg/kg body weight i.p.) and were transcardially perfused at room temperature (RT, 20-25°C) with phosphate buffered saline (0.1 M PBS, pH 7.4) for 20 s, followed by the fixative solution made up of 4% formaldehyde (freshly depolymerized from paraformaldehyde), 0.2% picric acid, and 0.1% glutaraldehyde in phosphate buffer (0.1 M PB, pH 7.4) for 10-15 min. Once the animals were perfused, the brains were numbered by a different experimenter to conduct the protocol blindly. Then, brains were removed from the skull and post-fixed in the fixative solution for approximately 1 week at 4°C. Afterwards, brains were stored at 4°C in 1:10 diluted fixative solution until used.

Pre-embedding silver-intensified immunogold method. The method applied was already described (Puente, 2019). Coronal midbrain vibratome sections containing the substantia nigra pars reticulata were cut at 50 μ m and collected in 0.1 M PB (pH 7.4) with 0.1% sodium azide at RT. Sections were preincubated in a blocking solution of 10% bovine serum albumin (BSA), 0.1% sodium azide, and 0.02% saponin prepared in Tris-HCl buffered saline (TBS 1X, pH 7.4) for 30 min at RT. Then, sections were incubated with a primary goat anti-CB₁ antibody binding to a 31 amino acids sequence of the C-terminus (CB₁ C-ter³¹; 2 μ g/ml; Cat. N.: CB₁-Go-Af450-1; Frontier Institute; Japan) in the blocking solution but with 0.004% saponin on a shaker for 1 day at RT. After several washes in 1% BSA/TBS, tissue sections were incubated in a secondary anti-goat 1.4 nm gold-labeled Immunoglobulin-G antibody (Fab' fragment, 1:100, Nanoprobes Inc.) in 1% BSA/TBS with 0.004% saponin on a shaker for 4 h at RT. Thereafter, the tissue was washed in 1% BSA/TBS overnight at 4°C and post-fixed in 1% glutaraldehyde in TBS for 10 min at RT. Following washes in double distilled water, gold particles were silver-intensified with a HQ Silver kit (Nanoprobes Inc., Yaphank, NY, USA) for about 12 min in the dark and then washed in 0.1 M PB (pH 7.4). Stained sections were osmicated (1% osmium tetroxide, OsO₄, in 0.1 M PB pH 7.4, 20 min), dehydrated in graded alcohols to propylene oxide, and plastic-embedded flat in Epon 812. To localize the region of interest, immunolabeled resin-embedded vibratome sections were first visualized by light microscopy to select the portion of the SN and to ensure that the slices have the appropriate antibody labeling. Then, semithin (700 nm) sections are mainly extracted to remove the resin and reach the tissue. Afterwards, we started to collect ultrathin sections of 50 nm on mesh nickel

1 grids, stained with 2.5% lead citrate for 20 min, and examined in a Philips
2 EM208S electron microscope. Photographs are always taken in the area of
3 interest and close to the resin; in this way we know that we are a few
4 nanometers from the surface, and that the immunelabeling is complete.
5 Furthermore, we photographed in a range of 0 to at most 950 nm from the
6 surface, because the first 5 ultrathin sections of 50 nm are collected. Tissue
7 preparations were photographed by using a digital camera coupled to the
8 electron microscope. Figure compositions were made at 300 dots per inch (dpi).
9 Labeling and minor adjustments in contrast and brightness were made using
10 Adobe Photoshop (CS, Adobe Systems, San Jose, CA, USA).

11 *Semi-quantification of mtCB₁ receptor immunostaining using immunogold*

12 *method.* Analyses were carried out according to previous publications
13 (Gutierrez-Rodriguez et al., 2018; Hebert-Chatelain et al., 2016; Puente et al.,
14 2019). 2-3 of 50 µm-thick sections containing the substantia nigra pars
15 reticulata and hippocampus from each animal genotype (n=3 each) showing
16 good and reproducible silver-intensified gold particles were cut at 50 nm. To
17 minimize differences between groups, all sections were processed
18 simultaneously. Three separate experiments were performed for each animal.
19 Electron micrographs were taken from grids with similar labeling intensity
20 indicating that selected areas were at the same depth. To avoid false negatives,
21 only ultrathin sections in the first 1.5 µm from the surface were examined. Total
22 CB₁ receptor labeling and total CB₁ particles in plasma and mitochondrial
23 membranes were counted per area. The proportion of CB₁ receptor-positive
24 mitochondria was calculated for each mouse counting only particles (at least
25 one) on mitochondrial membrane segments far away from other membranes

(distance $\geq$ 80 nm). Image-J (version 1.36) was used to measure the distance. Graphs and statistical analyses were performed using GraphPad software (version 5.0).

***In vitro* characterization of mt-sAC and PKA mutants**

Confocal Microscopy Imaging. HeLa cells seeded on 12-mm round glass coverslips and transfected as indicated, were placed on the stage of the Olympus FV3000 confocal fluorescence microscope (Tokyo, Japan) and imaged using a 60X oil objective (UPLAN 60x oil, 1.35 NA, Olympus), and appropriate excitation laser and filters. For each experiment, 15 cells were randomly selected and analyzed. Stacks of 30 images separated by 0.2 μ m along the Z axis were acquired. Three-dimensional reconstruction and volume rendering of the stacks were carried out with the appropriate plug-in of ImageJ (NIH, Bethesda, MD, USA). Pearson's correlation coefficient for TOM20 fluorescence colocalization with Myc or HA, was calculated with the Colocalization threshold tool of ImageJ.

Trypsin Sensitivity Assay. The trypsin sensitivity assay was carried out as described previously (Choo, 2004) with minor modifications. Isolation of mitochondrial fractions was performed as described previously (Guedouari et al., 2017). Briefly, HeLa cells were harvested and resuspended in mitochondrial isolation buffer (250 mM sucrose, 1 mM EDTA, 5 mM HEPES, pH 7.4) supplemented with 1% protease inhibitor cocktail (Bioshop, ON, Canada), 2 mM sodium orthovanadate and 1 mM sodium fluoride. Cells were lysed with 15 strokes using a 25-gauge syringe on ice and centrifuged at 1500x g for 5 min (4 °C). The resulting supernatant was centrifuged at 12,500x g for 10 min (4 °C). pellet was resuspended in the mitochondrial buffer and a cycle of centrifugation

at 1500× g and 12,500× g was repeated. The final pellet was considered as the mitochondria-enriched fraction. Protein concentration was determined by Bradford assay (Bradford, 1976). Isolated mitochondria were suspended in mitochondrial isolation buffer and incubated at 37 °C for 10 min in presence or absence of trypsin (0.5%) and triton X-100 (1%). Reaction was stopped by the addition of 1% of the protease inhibitor cocktail. Mitochondria were then centrifuged at 12,500× g at 4 °C for 10 min. The pellets were processed for SDS-PAGE and subsequent western blotting.

Sniffer cells detection of Substance-P release

cDNA for human NK₁ was purchased from the cDNA resource center (www.cdna.org). NK₁-mCherry plasmid was created by cloning the mCherry coding sequence in frame with the C-terminus of NK₁ with its stop codon removed by PCR.

System validation in vitro. NK₁-mCherry was co-transfected with GCaMP6s (Addgene) into HEK293 cells (Cedarlane) seeded on coverslips using Lipofectamine 2000 (Invitrogen). 24-48 hours later, coverslips were transferred to a perfusion chamber containing EBS (in mM: NaCl 140, KCl 5.4, CaCl₂ 1.3, HEPES 10, glucose 33, pH 7.35) and allowed to equilibrate for 10-15 minutes at room temperature with a flow rate of ~1ml/min. Baseline GCaMP6s fluorescence was recorded for 60 seconds. Then Substance-P (Tocris) was added to the chamber using a micropipette to achieve final concentrations of 10⁻¹¹M-10⁻⁶M. 16-bit Images were collected at 1Hz on an Olympus BX-61 microscope with a 20X water immersion objective and a Hamamatsu ORCA-Flash4 CCD camera. Using ImageJ, the change in fluorescence normalized to baseline fluorescence ($\Delta F/F_0$) was calculated following background subtraction

by binning the 30 frames prior to Substance-P stimulation (F0) and 30 frames surrounding the peak response following Substance-P stimulation. The perfusion chamber was washed with 50mL of EBS over 15 minutes between coverslips. When necessary, rundown was corrected using the Bleach Correction algorithm in ImageJ and the occasional flicker of the microscope bulb was corrected manually.

Substance-P and WIN 55,212-2 effect in vitro. HEK cells were seeded on glass coverslips coated with poly-lysine and transfected with plasmid DNA for NK₁-mCherry and GCaMP6s or Empty vector and GCaMP6s with PEI (**Figure S1I**).

Cells were imaged 24-48 hrs after transfection on epifluorescence mode with an inverted spinning-disk microscope equipped with 40X objective (NA 1.4), a multi-LED illumination system and a CDD camera. Coverslips were mounted on a open chamber and superfused with a buffer solution of (in mM): 112 NaCl, 5 KCl, 24 NaHCO₃, 10 HEPES, 1.25 CaCl₂, 1.25 MgCl₂, 5 glucose, bubbled with air/5% CO₂ (pH 7.4) at 36°C. For experiments on cells expressing NK₁-mCherry/ GCaMP6s, cells expressing NK₁ were first selected by 570 nm illumination and emission collection at 617/36 nm before starting Ca²⁺ imaging. Cells expressing GCaMP6s were excited at 490 nm for 0.05-0.1 s and emission collected at 524/16 nm. Data was background corrected and represented as normalized fluorescence. Substance-P and WIN55.212-2 were applied for 1 minute and recording were performed for the next 5 minutes (**Figure S1L**).

Substance-P release from striatonigral terminals. Sagittal sections containing SNr were prepared from 6 to 12 weeks-old mice. For electrical stimulation, naive CB₁-KO, DN22-CB₁-KI, and respective WT littermates were used. For optogenetic activation of striatonigral terminals 6 weeks-old D1-Cre mice were

1 used to target striatal neurons with injection of a rAAV-hSyn-DIO-ChrimsonR-
2 tdTomato into the dorsal Striatum (in mm relative to bregma: AP=+0.8, L=±2.0,
3 DV=-2.7) 6 weeks before experiments.

4 Mice were first sedated by inhaling isoflurane (4%) for approximately 30 s and
5 then deeply anesthetized with a mixture of ketamine and xylazine (100 and 20
6 mg/kg, i.p., respectively). After the disappearance of the reflexes, a thoracotomy
7 was performed to allow transcardial perfusion of a saturated (95% O₂/5% CO₂)
8 ice-cold solution containing 250 mM sucrose, 10 mM MgSO₄·7H₂O, 2.5 mM
9 KCl, 1.25 mM NaH₂PO₄·H₂O, 0.5 mM CaCl₂·H₂O, 1.3 mM MgCl₂, 26 mM
10 NaHCO₃ and 10 mM D-glucose. After decapitation, each brain was quickly
11 removed and cut into sagittal slices (300 µm) using a vibratome (VT-1200S;
12 Leica Microsystems, Germany). The slices were then incubated at 34°C for 10
13 min in a standard artificial cerebrospinal fluid (ACSF) saturated by bubbling
14 95% O₂/5% CO₂ and containing 126 mM NaCl, 2.5 mM KCl, 1.25 mM
15 NaH₂PO₄·H₂O, 2 mM CaCl₂·H₂O, 2 mM MgSO₄·7H₂O, 26 mM NaHCO₃ and 10
16 mM D-glucose, supplemented with 5 µM glutathion and 1 mM sodium pyruvate.

17 Transfected HEK cells (*see above*) re-suspended in ACSF were gently
18 deposited over the slices that were placed in a small petri-dish. Slices were
19 allowed to rest for 2h to allow the sniffer cells to attach to the tissue before
20 starting the recording. Slices were then transferred in a recording chamber
21 under an upright microscope (Ni-E, Nikon Instruments). For electrical
22 stimulation experiments, a bipolar stimulating electrode was placed in proximity
23 of *capsula interna* and trains of electrical stimulation were applied. For
24 optogenetic activation, an optic fiber was placed above the SNr and trains of
25 570nm light pulses (5s 20 Hz) were applied. The presence of the receptor and

the fluorescence of GCaMP6s in HEK cells were observed and measured with an infrared differential interference system using a 60x immersion lens. The image detection was done with a camera (Zyla, Andor technology). GCaMP6s was excited using 470 nm light supplied by a LED device (Lumencor). Images were collected at 10 Hz. Image stacks were imported into Image J software where changes in fluorescence in HEK cell were measured over time. Images were post-processed to calculate ΔF . Regions of interest (ROI) corresponded to HEK cell visually identifiable and expressing both GCaMP6s and Substance-P Receptor were delimited. The fluorescence time course F of each ROI was measuring by averaging all pixels within the ROI. Background fluorescence was subtracted from all values. Fluorescence at various time points was expressed relative to baseline. Stimulus-induced changes in fluorescence were calculated from the maximum value observed during a 30 s period following the onset of the response and expressed relative to baseline (average of values collected 10 s before the electrical stimulation or 3 s before red-light stimulation). Negative controls on brain slices were performed either by using HEK cells transfected only with GCaMP6s and not NK1-R (see above) or by GCaMP6s/NK1-R expressing HEK cells in presence of the selective Substance-P Receptor blocker CP122721. Control experiments for whole-cell voltage-clamp recordings of oIPSCs were performed as described in the next session.

Electrophysiology

Optogenetic activation of striatonigral terminals. Male DN22- CB_1 -KI mice, CB_1 -KO mice and their WT littermates were used to target striatal neurons with injection of a AAV2-hSyn-ChR2(H134R)-mCherry into the dorsal Striatum (in

1 mm relative to bregma: AP=+0.8, L=±2.0, DV=-2.7) 8-9 weeks before electrophysiological recordings. Mice were sedated with isoflurane, deeply anesthetized with ketamine/xylazine (75/10 mg/Kg) and perfused transcardially with ice-cold modified artificial cerebrospinal fluid (ACSF), equilibrated with 95% O₂ and 5% CO₂, and containing (in mM): 230 sucrose, 26 NaHCO₃, 2.5 KCl, 1.25 NaH₂PO₄, 0.5 CaCl₂, 10 MgSO₄ and 10 glucose. Brains were rapidly removed and sectioned into 300 µm-thick parasagittal slices with a vibrating blade microtome (VT1200S; Leica Microsystems, Germany). Slices containing the SNr were then left to equilibrate for 1 h (at 35°C) in ACSF of the following composition (in mM except otherwise specified): 126 NaCl, 26 NaHCO₃, 2.5 KCl, 1.25 NaH₂PO₄, 2 CaCl₂, 2 MgSO₄, 10 glucose, 1 sodium pyruvate and 4.9µM L-gluthathione reduced (gassed with 95% O₂ and 5% CO₂). Single slices were transferred to a recording chamber, perfused continuously with modified oxygenated ACSF at 32-34°C containing (in mM): 126 NaCl, 26 NaHCO₃, 3 KCl, 1.25 NaH₂PO₄, 1.6 CaCl₂, 1.5 MgSO₄, 10 glucose, and visualized using infrared gradient contrast video microscopy and a 60X water-immersion objective (Fluor 60X/1.00 W, Nikon). Recordings from individual SNr neurons were made using pipettes (impedance, 6-8 MΩ) prepared from borosilicate glass capillaries (G150-4; Warner Instruments, Hamden, CT, USA) with a micropipette puller (P-97; Sutter Instruments, Novato, CA, USA). For whole-cell voltage-clamp recordings, pipettes were filled with (in mM): 130 K-gluconate, 6.6 Na-gluconate, 1 MgCl₂·6H₂O, 10 HEPES, 5 QX-314, 0.1 Na₄EGTA, 0.4 Na₃GTP, 2 Mg_{1.5}ATP and 5.4 biocytin. The pipette solution had a pH of 7.2 and an osmolarity of 292 mOsm. Recordings were obtained using a Multiclamp 700B amplifier and Digidata 1440 digitizer controlled by Clampex 10.3

(Molecular Devices, Sunnyvale, CA, USA). Signals were low-pass filtered at 4 kHz and sampled at 20 kHz. Whole-cell voltage clamp recordings with Kgluconate-filled electrodes were corrected for a junction potential of 13 mV. In voltage clamp experiments, series resistance was monitored by a step of -5 mV at the end of each recording. Optogenetic activation of SNr terminals was performed *via* optic fiber as previously described (Froux et al., 2018)

After 5 minutes baseline, CB₁ receptor was activated with 5 μ M WIN 55,212-2 dissolved in DMSO. This concentration has been previously showed to reduce hippocampal EPSCs in a CB₁ dependent manner(Hebert-Chatelain et al., 2016). The glutamatergic synaptic transmission was not blocked for all electrophysiological experiments. Levels of drug-induced depression in response to WIN 55,212-2 are reported as averaged IPSC amplitudes for 5 min just before bath application compared with averaged IPSC amplitudes during the 15-min period after the application. Data were discarded when the series resistance varied by >20%. After electrophysiological recordings, slices were fixed overnight in a solution of paraformaldehyde at 4% and maintained in PBS-azide at 0.3% at 4°C until histological processing for mCherry visualization or TH/biocytyin immunostaining(Chazalon et al., 2018).

Hippocampal depolarization-induced suppression of inhibition. Male DN22-CB₁-KI mice and their WT littermates were sacrificed by dislocation and the brain was immediately immersed in ice-cold oxygenated cutting solution containing in mM: 180 Sucrose, 26 NaHCO₃, 12 MgSO₄, 11 Glucose, 2.5 KCl, 1.25 NaH₂PO₄, and 0.2 CaCl₂, oxygenated with 95% O₂-5% CO₂ $\approx$ 300mOsm. Parasagittal hippocampal slices (300 μ m thick) were obtained using a vibratome (VT1200S, Leica, Germany) and transferred for 30min into a 34°C bath of

oxygenated ACSF containing in mM: 123 NaCl, 26 NaHCO₃, 11 Glucose, 2.5 KCl, 2.5 CaCl₂, 1.3 MgCl₂, 1.25 NaH₂PO₄ ≈305 mOsm. After a minimum of 1h recovery at room temperature (22-25°C), slices were transferred to a recording chamber in ACSF at 32°C. Whole-cell recordings of IPSCs were made using a MultiClamp 700B amplifier (Molecular devices, UK) in CA1 pyramidal neurons voltage clamped at -70mV with a pipette (3-5 MΩ) containing in mM: 130 KCl, 10 HEPES, 1 EGTA, 2 MgCl₂, 0.3 CaCl₂, 7 Phosphocreatin, 3 Mg-ATP, 0.3 Na-GTP; pH = 7.2; 290mOsm. Evoked IPSCs were performed by a monopolar stimulating patch pipette filled with ACSF in stratum radiatum in presence of NMDA and AMPA/Kainate receptor antagonists (50μM D-APV and 10μM NBQX).

DSIs were performed by depolarizing pyramidal neurons from -70mV to 0mV for 3 s. DSIs' magnitude were measured as the average of 3 DSIs with 2min apart and represented the percentage of change between the mean of the 5 consecutive IPSCs preceding the depolarization and the first three IPSCs following the depolarization, with IPSCs evoked every 3 s. Currents were filtered at 4kHz by a Digidata 1440A (Molecular devices, UK) and were analyzed using either Clampfit software (pClamp10).

Data collection and statistical analyses

No statistical methods were used to pre-determine sample sizes, but they are similar to those reported in previous publications. Data collection and analysis were performed blind to the conditions of the experiment. All mice were assigned randomly to the different experimental conditions.

1 All graphs and statistical analyses were performed using GraphPad software
2 (version 5.0, 6.0 or 8.0). Results were expressed as means of independent data
3 points $\pm$ s.e.m. Behavioral data were checked for normality distribution with the
4 D'Agostino&Pearson test. When all groups of an experiment passed the
5 normality test, ANOVA (One-way or Two-way, where appropriate) analysis was
6 performed and when interaction was significant Tukey's post hoc analysis was
7 used. When the normality was rejected, non-parametric One-way ANOVA
8 (Kruskal-Wallis) was used (**Table S2 and S3**). Biochemical, anatomical,
9 imaging and electrophysiological data were analyzed using Student's *t*-test
10 (unpaired or paired, where appropriate) or Wilcoxon test as appropriate (**Table**
11 **S2 and S3**). Post hoc significances were expressed as follow: * $p<0.05$, **
12 $p<0.01$, *** $p<0.001$.

FIGURE LEGENDS

Figure 1. Striatonigral CB₁ receptors mediate catalepsy and antinociception.

(A and B) Effects of correct “hit” or misplaced “no-hit” intra-SNr administration of the cell permeable CB₁ antagonist AM251 on the **(A)** cataleptic, and **(B)** antinociceptive THC effect (10mg/kg i.p.) respect to vehicle treated mice.

(C) Representative micrograph (left) and relative quantification (right) of CB₁ immunoreactivity in the GPe (white bars) and the SNr (black bars) of mice with striatopallidal (ST-GP-CB₁-KO) or striatonigral (ST-SN-CB₁-KO) CB₁ receptor deletion compared to control littermates. Target regions are indicated by yellow dotted lines.

(D) Cataleptic and **(E)** antinociceptive effects of THC (10mg/kg i.p.) in mice with striatopallidal (ST-GP-CB₁-KO) or striatonigral (ST-SN-CB₁-KO) CB₁ receptor deletion compared to control littermates.

(F and G) Effects of intra-SNr administration of the cell impermeable CB₁ antagonist Hemopressin (Hp) on the **(F)** cataleptic, and **(G)** antinociceptive effect of systemic THC (10mg/kg i.p.) respect to vehicle treated mice.

(H and I) Effects of intra-SNr administration of the NK₁ receptor agonist GR73632 on the **(H)** cataleptic, and **(I)** antinociceptive effect of THC (10mg/kg i.p.) respect to vehicle treated mice.

(J) Schematic representation of the Substance-P sniffer strategy, and representative picture of sniffers cells [HEK cell expressing NK₁ receptor

(NK₁R) (red) and GCaMP6 (green)] deposited over slices (IR). Stim: electrical stimulation, STR: striatum, SNr: Substantia nigra pars reticulata, GPe: external globus pallidus. Scale bars: 50 μ m.

(K) Left: Representative GCaMP6 fluorescence in the SNr before and after electrical stimulation, in presence of vehicle or WIN (5 μ M). Middle: traces of GCaMP6 fluorescence variation ($\Delta F/F_0$) from sniffer cells overlying the area shown in **(K)** (right panel, white square) in the absence (Vehicle) and in the presence of WIN when electrical stimulation (gray bars) of the striatonigral pathway is applied in both WT and *CB₁*-KO littermates. Plots are from the same cells in both conditions. Right: summary graphs comparing ΔF induced by electrical stimulation in all sniffer cells responding and imaged over the SNr in Vehicle and WIN conditions, comparing WT vs *CB₁*-KO littermates.

(L) Schematic representation of the Substance-P sniffer strategy coupled to optogenetic stimulation of striatonigral terminals. SNr: Substantia nigra pars reticulata, GPe: external globus pallidus.

(M) Left: traces of GCaMP6 fluorescence variation ($\Delta F/F_0$) from sniffer cells overlying the SNr in the absence (Vehicle) and in the presence of WIN when light stimulation (red bars) of the striatonigral pathway is applied. Plots are from the same cells in both conditions. Right: summary graphs comparing ΔF induced by light stimulation in all sniffer cells responding and imaged over the SNr in Vehicle and WIN conditions.

Figure 2. CB₁ receptor subcellular localization in the SNr.

(A - E) Immunogold detection of CB₁ receptor by electron microscopy in WT and CB₁-KO mice in SNr. White arrows, plasma membrane gold particles; pink arrows, mitochondrial gold particles; scale bar: 500 nm. Den, dendrites; ter, synaptic terminal, m, mitochondrion; red arrowheads, synapses. Relative quantifications of total CB₁ receptor labeling **(B)**, plasma membrane CB₁ (pmCB₁) receptor labeling **(C)**, mitochondrial-associated CB₁ (mtCB₁) receptor labeling **(D)** and proportion of CB₁ receptor-positive mitochondria **(E)**.

(F - J) Immunogold detection of CB₁ receptor by electron microscopy in WT and DN22-CB₁-KI mice in SNr. White arrows, plasma membrane gold particles; pink arrows, mitochondrial gold particles; scale bar: 500 nm. Den, dendrites; ter, synaptic terminal, m, mitochondrion; red arrowheads, synapses. Relative quantifications of total CB₁ receptor labeling **(G)**, plasma membrane CB₁ (pmCB₁) receptor labeling **(H)**, mitochondrial-associated CB₁ (mtCB₁) receptor labeling **(I)** and proportion of CB₁ receptor-positive mitochondria **(J)**.

(K) Concentration–response curves of the effect of WIN on [³⁵S]GTPγS binding in membranes isolated from cortex, hippocampus and midbrain of WT, CB₁-KO and DN22-CB₁-KI mice.

(L) The effect of WIN (1μM) on mitochondrial respiration (oxygen consumption rate, OCR) in SNr homogenates from WT, CB₁-KO, and DN22-CB₁-KI mice. Data are expressed as percentage of vehicle values.

Figure 3. Striatonigral mtCB₁ receptor functions.

(A) Representative picture of the striatonigral pathway targeted with optogenetic tools. STR, striatum; GPe, external globus pallidus; STN, subthalamic nucleus; TH, thalamus; HP, hippocampus; SNr substantia nigra pars reticulata. Scale bar 500µM.

(B) Representative post-hoc characterization of the analyzed cells (white arrow) by immunofluorescence for biocytin, mCherry (ChR2) and thyroxine-hydroxylase (TH). Scale bar: 50µM.

(C) Representative traces of light evoked inhibitory post-synaptic currents (oIPSCs) under control condition and in presence of the GABA_A receptor blocker Gabazine (GBZ) with its corresponding time-course effect.

(D) Time course effect of WIN (5 µM) on striatonigral oIPSCs in slices derived from WT, CB₁-KO and DN22-CB₁-KI mice.

(E) Plots of normalized oIPSCs with representative traces before and after WIN treatment and summary of the average change of oIPSCs relative to baseline.

(F) Cataleptic, and **(G)** antinociceptive effect of systemic THC (10mg/kg i.p.) or WIN (3mg/kg i.p.), respect to vehicle in WT and DN22-CB₁-KI mice

Figure 4. Striatonigral mtCB₁ receptor signaling.

(A) Schematic representation of the CB₁ or DN22-CB₁ rescue-approach in D₁-CB₁-KO mice. STR, striatum; SNr, substantia nigra pars reticulata; mtCB₁, mitochondrial CB₁ receptor; pmCB₁, plasma membrane CB₁ receptor.

(B) Representative immunofluorescence pictures of CB₁ or DN22-CB₁ rescue in the SNr of D₁-CB₁-KO mice. Green, CB₁ positive signal; Blue, DAPI nuclear counterstaining. Scale bar 250µm.

(C) Relative quantification of CB₁ receptor immunofluorescence D₁-CB₁-KO mice after CB₁ or DN22-CB₁ rescue in the SNr.

(D) Effect of WIN (1µM) on mitochondrial respiration (oxygen consumption rate, OCR) in SN homogenates from WT, D₁-CB₁-KO control mice, and CB₁ or DN22-CB₁ rescued in the striatonigral circuit (*see above A and B*).

(E) Cataleptic effect of THC (10mg/kg i.p.) in WT, D₁-CB₁-KO control mice, and CB₁ or DN22-CB₁ rescued in the striatonigral circuit (*see above A and B*).

(F) Effect of WIN (1µM) on mitochondrial respiration (oxygen consumption rate, OCR) in SN homogenates pre-treated with vehicle or the sAC blocker KH7 (5µM).

(G and H) Effects of intra-SNr administration of sAC blocker KH7 (2µg) on the **(G)** cataleptic, and **(H)** antinociceptive effect of systemic THC (10mg/kg i.p.) respect to vehicle treated mice.

1 **(I)** Effect of WIN (1 μ M) on mitochondrial respiration (oxygen consumption rate,
2 OCR) in SN homogenates from D₁-Cre mice injected in the striatum with control
3 (Ctr) virus or Cre-dependent mt-sAC expressing virus.

4 **(J)** Cataleptic, and **(K)** antinociceptive effects of systemic THC (10mg/kg i.p.)
5 respect to vehicle in D₁-Cre mice injected with either control (Ctr) or Cre-
6 dependent mt-sAC expressing virus in the striatum.

7 **(L)** Cataleptic, and **(M)** antinociceptive effect of systemic THC (10mg/kg i.p.)
8 respect to vehicle in D₁-Cre mice injected with either control (Ctr) or Cre-
9 dependent PKA-CA or MLS-PKA-CA expressing virus in the striatum.

10 **(N)** Effect of WIN (1 μ m) on mitochondrial respiration (oxygen consumption rate,
11 OCR) in SN homogenates from D₁-Cre mice injected in the striatum with control
12 virus or Cre-dependent PKA-CA or MLS-PKA-CA vectors.

SUPPLEMENTARY FIGURE LEGENDS

Figure S1 (related to main Figure 1). Cannabinoid-induced antinociception, but not catalepsy, relies on activation of striatonigral pmCB₁ and regulation of Substance-P/NK₁ receptor activity.

(A) SNr correct (hit) and misplaced (no-hit) cannula placements verified by infusion of skyblue toluidine solution followed by brain slicing and neutral red counterstaining. Representative histological analysis (top) and schematic representations (bottom, “hit” green dots, “no-hit” red dots) of the injection sites in the SNr.

(B) Effects of correct “hit” and misplaced “no-hit” intra-SNr administration of the cell permeable CB₁ antagonist AM251 on the hypolocomotor effect of systemic THC (10mg/kg i.p.) respect to vehicle treated mice.

(C) Schematic for striatonigral or striatopallidal CB₁ receptor deletion and representative pictures of viral injection sites. Green signal, striatal (STR) expression of AAV-FRT-iCre-EGFP. Blue signal, AAV-retro-FLP-BLFP or AAV-retro-BLFP expression in the globus pallidus (GPe) or in the substantia nigra reticulata (SNr).

(D) Representative micrograph (left) and relative quantification (right) of CB₁/D₁ and CB₁/D₂ co-expressing cells in the striatum of mice with striatopallidal (ST-GP-CB₁-KO) or striatonigral (ST-SN-CB₁-KO) CB₁ receptor deletion compared to control littermates. ec: external capsule. ns: non–statistically different. Scale bar, 50µm.

1 **(E)** Hypolocomotor effect of systemic THC (10mg/kg i.p.) respect to vehicle in
2 mice with striatopallidal (ST-GP-*CB₁*-KO) or striatonigral (ST-SN-*CB₁*-KO) *CB₁*
3 receptor deletion compared to control littermates.

4 **(F-G)** Effects of i.p. administration of the *NK₁* receptor agonist GR73632 (75
5 µg/kg) on the cataleptic **(F)** and antinociceptive **(G)** effects of systemic THC
6 (10mg/kg i.p.) respect to vehicle treated mice.

7 **(H)** Left: Schematics of the Substance-P (SP) “sniffer cell” system. Co-
8 expression of human *NK₁* receptor (h*NK₁*R) and GCaMP6s in HEK293T cells
9 facilitates detection of SP-induced calcium increases reflected by increased
10 GCaMP6s fluorescence. Center: fluorescence micrographs of representative
11 SP “sniffer cells” co-expressing h*NK₁*R-mCherry and GCaMP6s, and line-scan
12 fluorescence quantification indicating membrane localization of h*NK₁*R. Right:
13 representative fluorescence micrographs and kinetic trace of SP “sniffer cells” at
14 baseline (time=0s) and following stimulation with 10nM SP (time=180s) added
15 to the perfusion chamber following a 60s baseline recording. Dose response to
16 SP in the same settings (bottom right) quantified as the change in GCaMP6s
17 fluorescence normalized to baseline fluorescence ($\Delta F/F_0$) with increasing doses
18 of SP. The EC₅₀ for “sniffer cells” to SP was 5.088nM.

19 **(I)** GCaMP6 response to different doses of SP in presence of *NK₁*R or in its
20 absence, indicating the specificity of the “sniffer cell” response.

21 **(J)** Left: traces of GCaMP6 fluorescence variation ($\Delta F/F_0$) from sniffer cells
22 expressing only GCaMP6 or both GCaMP6/*NK₁*R in the absence (Vehicle) and
23 in the presence of the *NK₁*R blocker CP122721 (CP) when electrical stimulation
24 (gray bars) of the striatonigral pathway is applied. Right: summary bar graphs

1 comparing means $\pm$ SE values of ΔF induced by electrical stimulation in all
2 sniffer cells responding and imaged over the SNr in Vehicle and CP conditions
3 **(K)** GCaMP6 fluorescence changes (ΔF) after electrical stimulation in control
4 condition, after vehicle and 5 μ M WIN on the same cells.
5 **(L)** Induction of calcium increase by SP in presence of 5 μ M WIN *in vitro*.
6 **(M)** Representative traces of light evoked inhibitory post-synaptic currents
7 (oIPSCs) in the SNr of D₁-Cre mice injected in the striatum with rAAV-DIO-
8 ChrmisonR as explained in **Figure 1L**. Note the presence of small oIPSCs
9 induced by blue light application using during calcium imaging.

Figure S2 (related to main Figure 2). Functional localization of CB₁ receptors at mitochondrial membranes within the SNr.

(A) Immunogold detection of CB₁ receptor by electron microscopy in WT and CB₁-KO mice in SNr. White arrows, plasma membrane gold particles; pink arrows, mitochondrial gold particles; scale bar: 500 nm.

(B) Schematic representation of the strategy employed for the generation of DN22-CB₁-KI mouse line. LHA: left homology arm; RHA, right homology arm.

(C) Top left: qRT-PCR analysis of CB₁ mRNA in different brain regions from WT, DN22-CB₁-KI and CB₁-KO mice. AMY, amygdala; HYP, hypothalamus; STR, striatum; HPC, hippocampus; AON, anterior olfactory nucleus; PFC, prefrontal cortex. n.d., not detected Top right and bottom: immunofluorescence detection and representative images of CB₁ receptor in the brain of WT vs DN22-CB₁-KI mice (CB₁-KO mice are shown as antibody negative control). CA1, hippocampal region; SNr, substantia nigra pars reticulata; STR, striatum; MC, motor cortex; AON, anterior olfactory nucleus; PFC, prefrontal cortex; CRB, cerebellum.

(D) Immunogold detection of CB₁ receptor by electron microscopy in WT and DN22-CB₁-KI mice in SNr. White arrows, plasma membrane gold particles; pink arrows, mitochondrial gold particles; scale bar: 500 nm.

(E) Representative autoradiograms of brain sections from basal, 1 μM and 10 μM WIN-stimulated [³⁵S]GTPγS binding in WT mice.

(F) Relative quantification of WIN-mediated [³⁵S]GTPγS over basal level at 1μM (left) and 10μM (right) doses in WT and DN22-CB₁-KI mice. SNr, substantia nigra reticulata; STR, striatum; PFC, prefrontal cortex; OB, olfactory bulb; HYP,

hypothalamus; GPe, external globus pallidus; HPC, hippocampus; CB, cerebellum; BLA, basolateral amygdala; AON, anterior olfactory nucleus; NAC, nucleus accumbens.

(G) Representative autoradiograms of brain sections from WT, DN22- CB_1 -KI and CB_1 -KO mice incubated with [3H] CP55.940.

(H) Relative quantification of bound [3H] CP55.940 in WT, DN22- CB_1 -KI and CB_1 -KO slices. SNr, substantia nigra pars reticulata; STR, striatum; PFC, prefrontal cortex; OB, olfactory bulb; HYP, hypothalamus; GPe, external globus pallidus; HPC, hippocampus; CB, cerebellum; BLA, basolateral amygdala; AON, anterior olfactory nucleus; NAC, nucleus accumbens.

(I) Representative trace of mitochondrial respiration in a substantia nigra preparation from WT, DN22- CB_1 -KI and CB_1 -KO mice. Substrates are malate, pyruvate and glutamate. The inhibitory effect of WIN was observed when the respiration was coupled to ATP synthesis via the addition of Adenosine diphosphate (ADP, see **Table S1**).

Figure S3 (related to main Figure 3). MtCB₁ receptors and their signaling mediate the cataleptic effect of cannabinoids in the striatonigral circuits.

(A) Body weight (top panel) and muscular strength (measured by grid suspension test, bottom panel) of WT and DN22-CB₁-KI mice.

(B) Daily home cage locomotor activity of WT and DN22-CB₁-KI mice. Grey box indicate the night phase.

(C) Daily voluntary wheel running of WT and DN22-CB₁-KI mice. Grey box indicate the night phase.

(D) Time course plot showing eIPSCs amplitude before and after 3s depolarization (-70 to 0 mV grey line) in hippocampal slices obtained from WT and DN22-CB₁-KI mice.

(E) Representative traces of eIPSCs before and after 3s depolarization (-70 to 0 mV) in WT and DN22-CB₁-KI mice and averaged reduction of eIPSCs amplitude respect to baseline recorded during 3 sweeps after depolarization.

(F) Average paired pulse ratio (PPR) after optogenetic stimulation of striatonigral terminals in WT and DN22-CB₁-KI mice.

(G) Traces of GCaMP6 fluorescence variation ($\Delta F/F_0$) from sniffer cells in the absence (Vehicle) and in the presence of WIN when electrical stimulation (gray bars) of the striatonigral pathway in slices from DN22-CB₁-KI mice is applied. Plots are from the same cells in both conditions. Right: summary bar graphs comparing means $\pm$ SEM values of $\Delta F/F_0$ induced by electrical stimulation in all

1 sniffer cells responding and imaged over the SNr in Vehicle and WIN conditions
2 in DN22- CB_1 -KI mice.

3 **(H)** Effects of intra-SNr administration of the cell impermeable CB_1 antagonist
4 Hemopressin (Hp, 22ng) on the antinociceptive effect of systemic THC
5 (10mg/kg i.p.) in DN22- CB_1 -KI mice.

6 **(I)** Effects of i.p. administration of the NK_1 receptor agonist GR73632 (75 μ g/kg)
7 on the antinociceptive effect of systemic THC (10mg/kg i.p.) respect to vehicle
8 in DN22- CB_1 -KI mice.

9 **(J)** Correlation between CB_1 fluorescence intensity in SNr (X axis) and
10 immobility in the bar test induced by THC (Y axis) in D_1 - CB_1 -KO mice injected
11 with rAAV-DIO- CB_1 (black dots) or with rAAV-DIO-DN22- CB_1 (grey dots) in the
12 striatum.

13 **(K)** Effect of WIN (1 μ M) on mitochondrial respiration (oxygen consumption rate,
14 OCR) in SN homogenates pre-treated with vehicle or GR736321 (1 μ M).

15 **(L)** Representative immunofluorescence of the mitochondrial protein TOMM20
16 and HA in Hela cells expressing pcDNA or mt-sAC. Scale bar: 10 μ m.

17 **(M)** Representative pictures of HA-tag immunostaining in the dorsal striatum of
18 D_1 -Cre mice injected with control or Cre-dependent mt-sAC AAV. Scale bar
19 100 μ m.

20 **(N)** Western blotting for HA-tag, endogenous sAC, tubulin and Tomm20 after
21 immuno-magnetic isolation of striatal mitochondria (Mito) compared to total cell

1 lysate (TCL) from D₁-Cre mice injected with control or Cre-dependent mt-sAC
2 AAV in the dorsal striatum.

3 **(O)** Western blotting for HA-tag and endogenous sAC in SN homogenates
4 (used for mitochondrial respiration, see **Figure 4I**) from D₁-Cre mice injected
5 with control or Cre-dependent mt-sAC AAV in the dorsal striatum.

6 **(P)** Representative immunofluorescence and co-localization analysis of the
7 mitochondrial protein TOMM20 and Myc in Hela cells expressing pcDNA, PKA-
8 CA or MLS-PKA-CA. Scale bar: 10 µm. And Trypsin sensitivity assay (right).

9 **(Q)** Western blotting for Myc-tag, endogenous PKA, tubulin and Tomm20 after
10 immuno-magnetic isolation of striatal mitochondria (Mito) compared to total cell
11 lysate (TCL) from D₁-Cre mice injected with control or Cre-dependent PKA-CA
12 or MLS-PKA-CA AAVs in the dorsal striatum.

13 **(R)** Western blotting for myc-tag in SN homogenates (used for mitochondrial
14 respiration, see **Figure 4N**) from D₁-Cre mice injected with control or Cre-
15 dependent PKA-CA or MLS-PKA-CA AAVs in the dorsal striatum.

16

1 **Figure S4. Proposed mechanisms for the subcellular specificity of**
2 **behavior control by CB₁ receptors in striatonigral circuits.**

3 At striatonigral terminals, activation of pmCB1 triggers inhibition of cytosolic
4 PKA, which in turn results in a reduction of Substance-P release and
5 subsequent decrease of pain perception. In the same terminals, activation of
6 mtCB₁ is responsible of motor impairment, by decreasing the release of GABA
7 on SNr neurons through inhibition of mitochondrial activity.

8

1 **Table S1. Characterization of Mitochondrial respiration in SN extracts**

2 CI_L , ComplexI Leak; CI_P , ComplexI OXPHOS; $CI \& CII_P$, ComplexI and
3 ComplexII OXPHOS; CII_P , ComplexII OXPHOS; ROX, Residual Oxygen
4 Consumption.

5 **Table S2. Statistical analysis. Related to Figure 1-4.**

6 **Table S3. Statistical analysis. Related to Figure S1-S3.**

7

REFERENCES

- Bellochio, L., Lafenetre, P., Cannich, A., Cota, D., Puente, N., Grandes, P., Chaouloff, F., Piazza, P., and Marsicano, G. (2010). Bimodal control of stimulated food intake by the endocannabinoid system. *Nature Neuroscience* 13, 281–283.
- Bellochio, L., Ruiz-Calvo, A., Chiarlone, A., Cabanas, M., Resel, E., Cazalets, J.R., Blazquez, C., Cho, Y.H., Galve-Roperh, I., and Guzman, M. (2016). Sustained Gq-Protein Signaling Disrupts Striatal Circuits via JNK. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 36, 10611-10624.
- Benard, G., Massa, F., Puente, N., Lourenco, J., Bellochio, L., Soria-Gomez, E., Matias, I., Delamarre, A., Metna-Laurent, M., Cannich, A., *et al.* (2012). Mitochondrial CB(1) receptors regulate neuronal energy metabolism. *Nature neuroscience* 15, 558-564.
- Boccella, S., Marabese, I., Guida, F., Luongo, L., Maione, S., and Palazzo, E. (2020). The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum. *Curr Neuropharmacol* 18, 34-50.
- Borgelt, L.M., Franson, K.L., Nussbaum, A.M., and Wang, G.S. (2013). The pharmacologic and clinical effects of medical cannabis. *Pharmacotherapy* 33, 195-209.
- Borgkvist, A., and Fisone, G. (2007). Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons. *Neuroscience and biobehavioral reviews* 31, 79-88.

1 Borsook, D., Upadhyay, J., Chudler, E.H., and Becerra, L. (2010). A key role of
2 the basal ganglia in pain and analgesia--insights gained through human
3 functional imaging. *Mol Pain* 6, 27.

4 Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of
5 microgram quantities of protein utilizing the principle of protein-dye binding.
6 *Analytical Biochemistry* 72, 248–254.

7 Brown, R.E. (2019). Review of Franz Joseph Gall: Naturalist of the mind,
8 visionary of the brain. *Hist Psychol* 22, 374-379.

9 Bucko, P.J., Lombard, C.K., Rathbun, L., Garcia, I., Bhat, A., Wordeman, L.,
10 Smith, F.D., Maly, D.J., Hehnlly, H., and Scott, J.D. (2019). Subcellular drug
11 targeting illuminates local kinase action. *Elife* 8.

12 Busquets-Garcia, A., Bains, J., and Marsicano, G. (2018). CB1 Receptor
13 Signaling in the Brain: Extracting Specificity from Ubiquity.
14 *Neuropsychopharmacology : official publication of the American College of*
15 *Neuropsychopharmacology* 43, 4-20.

16 Chazalon, M., Paredes-Rodriguez, E., Morin, S., Martinez, A., Cristovao-
17 Ferreira, S., Vaz, S., Sebastiao, A., Panatier, A., Boue-Grabot, E., Miguelez, C.,
18 and Baufreton, J. (2018). GAT-3 Dysfunction Generates Tonic Inhibition in
19 External Globus Pallidus Neurons in Parkinsonian Rodents. *Cell Rep* 23, 1678-
20 1690.

21 Chen, W., Ennes, H.S., McRoberts, J.A., and Marvizon, J.C. (2018).
22 Mechanisms of mu-opioid receptor inhibition of NMDA receptor-induced
23 substance P release in the rat spinal cord. *Neuropharmacology* 128, 255-268.

1 Chomczynski, P., and Sacchi, N. (1987). Single-step method of RNA isolation
2 by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem*
3 162, 156-159.

4 Choo, Y.S. (2004). Mutant huntingtin directly increases susceptibility of
5 mitochondria to the calcium-induced permeability transition and cytochrome c
6 release. *Human Molecular Genetics* 13, 1407–1420.

7 Clapper, J.R., Moreno-Sanz, G., Russo, R., Guijarro, A., Vacondio, F., Duranti,
8 A., Tontini, A., Sanchini, S., Sciolino, N.R., Spradley, J.M., et al. (2010).
9 Anandamide suppresses pain initiation through a peripheral endocannabinoid
10 mechanism. *Nat Neurosci* 13, 1265–1270.

11 Cohen, K., Weizman, A., and Weinstein, A. (2019). Positive and Negative
12 Effects of Cannabis and Cannabinoids on Health. *Clin Pharmacol Ther* 105,
13 1139-1147.

14 Creighton, J. (2011). Targeting therapeutic effects: subcellular location matters.
15 Focus on "Pharmacological AMP-kinase activators have compartment-specific
16 effects on cell physiology". *Am J Physiol Cell Physiol* 301, C1293-1295.

17 Darmani, N.A., and Pandya, D.K. (2000). Involvement of other
18 neurotransmitters in behaviors induced by the cannabinoid CB1 receptor
19 antagonist SR 141716A in naive mice. *J Neural Transm (Vienna)* 107, 931-945.

20 Deniau, J.M., Mailly, P., Maurice, N., and Charpier, S. (2007). The pars
21 reticulata of the substantia nigra: a window to basal ganglia output. *Progress in*
22 *brain research* 160, 151-172.

23 Donvito, G., Nass, S.R., Wilkerson, J.L., Curry, Z.A., Schurman, L.D., Kinsey,
24 S.G., and Lichtman, A.H. (2018). The Endogenous Cannabinoid System: A
25 Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

1 Neuropsychopharmacology : official publication of the American College of
2 Neuropsychopharmacology 43, 52-79.

3 Dubreucq, S., Koehl, M., Abrous, D.N., Marsicano, G., and Chaouloff, F. (2010).
4 CB1 receptor deficiency decreases wheel-running activity: consequences on
5 emotional behaviours and hippocampal neurogenesis. *Exp Neurol* 224, 106-
6 113.

7 Dwivedi, Y., and Pandey, G.N. (2008). Adenylyl cyclase-cyclicAMP signaling in
8 mood disorders: role of the crucial phosphorylating enzyme protein kinase A.
9 *Neuropsychiatr Dis Treat* 4, 161-176.

10 Eichel, K., and von Zastrow, M. (2018). Subcellular Organization of GPCR
11 Signaling. *Trends Pharmacol Sci* 39, 200-208.

12 Fernandez-Ruiz, J., Moreno-Martet, M., Rodriguez-Cueto, C., Palomo-Garo, C.,
13 Gomez-Canas, M., Valdeolivas, S., Guaza, C., Romero, J., Guzman, M.,
14 Mechoulam, R., and Ramos, J.A. (2011). Prospects for cannabinoid therapies in
15 basal ganglia disorders. *Br J Pharmacol* 163, 1365-1378.

16 Francisco, A., Engel, D.F., Figueira, T.R., Rogerio, F., de Bem, A.F., and
17 Castilho, R.F. (2020). Mitochondrial NAD(P)(+) Transhydrogenase is Unevenly
18 Distributed in Different Brain Regions, and its Loss Causes Depressive-like
19 Behavior and Motor Dysfunction in Mice. *Neuroscience* 440, 210-229.

20 Freeze, B.S., Kravitz, A.V., Hammack, N., Berke, J.D., and Kreitzer, A.C.
21 (2013). Control of basal ganglia output by direct and indirect pathway projection
22 neurons. *The Journal of neuroscience : the official journal of the Society for*
23 *Neuroscience* 33, 18531-18539.

1 Garcia, C., Palomo-Garo, C., Gomez-Galvez, Y., and Fernandez-Ruiz, J.
2 (2016). Cannabinoid-dopamine interactions in the physiology and
3 physiopathology of the basal ganglia. *Br J Pharmacol* 173, 2069-2079.

4 Garcia, G.C., Bartol, T.M., Phan, S., Bushong, E.A., Perkins, G., Sejnowski,
5 T.J., Ellisman, M.H., and Skupin, A. (2019). Mitochondrial morphology provides
6 a mechanism for energy buffering at synapses. *Sci Rep* 9, 18306.

7 Giuffrida, A., and Seillier, A. (2012). New insights on endocannabinoid
8 transmission in psychomotor disorders. *Prog Neuropsychopharmacol Biol*
9 *Psychiatry* 38, 51-58.

10 Griebel, G., Stemmelin, J., and Scatton, B. (2005). Effects of the cannabinoid
11 CB1 receptor antagonist rimonabant in models of emotional reactivity in
12 rodents. *Biological Psychiatry* 57, 261–267.

13 Guedouari, H., Daigle, T., Scorrano, L., and Hebert-Chatelain, E. (2017). Sirtuin
14 5 protects mitochondria from fragmentation and degradation during starvation.
15 *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* 1864, 169–176.

16 Gutierrez-Rodriguez, A., Bonilla-Del Rio, I., Puente, N., Gomez-Urquijo, S.M.,
17 Fontaine, C.J., Egana-Huguet, J., Elezgarai, I., Ruehle, S., Lutz, B., Robin,
18 L.M., *et al.* (2018). Localization of the cannabinoid type-1 receptor in subcellular
19 astrocyte compartments of mutant mouse hippocampus. *Glia* 66, 1417-1431.

20 Häring, M., Kaiser, N., Monory, K., and Lutz, B. (2011). Circuit Specific
21 Functions of Cannabinoid CB1 Receptor in the Balance of Investigatory Drive
22 and Exploration. *PLoS ONE* 6, e26617.

23 Hebert-Chatelain, E., Desprez, T., Serrat, R., Bellocchio, L., Soria-Gomez, E.,
24 Busquets-Garcia, A., Pagano Zottola, A.C., Delamarre, A., Cannich, A., Vincent,

1 P., *et al.* (2016). A cannabinoid link between mitochondria and memory. *Nature*
2 539, 555-559.

3 Heimann, A.S., Gomes, I., Dale, C.S., Pagano, R.L., Gupta, A., de Souza, L.L.,
4 Luchessi, A.D., Castro, L.M., Giorgi, R., Rioli, V., *et al.* (2007). Hemopressin is
5 an inverse agonist of CB1 cannabinoid receptors. *Proceedings of the National*
6 *Academy of Sciences of the United States of America* 104, 20588-20593.

7 Ibsen, M.S., Connor, M., and Glass, M. (2017). Cannabinoid CB1 and CB2
8 Receptor Signaling and Bias. *Cannabis Cannabinoid Res* 2, 48-60.

9 Ilouz, R., Lev-Ram, V., Bushong, E.A., Stiles, T.L., Friedmann-Morvinski, D.,
10 Douglas, C., Goldberg, J.L., Ellisman, M.H., and Taylor, S.S. (2017). Isoform-
11 specific subcellular localization and function of protein kinase A identified by
12 mosaic imaging of mouse brain. *Elife* 6.

13 Jimenez-Blasco, D., Busquets-Garcia, A., Hebert-Chatelain, E., Serrat, R.,
14 Vicente-Gutierrez, C., Ioannidou, C., Gomez-Sotres, P., Lopez-Fabuel, I.,
15 Resch-Beusher, M., Resel, E., *et al.* (2020). Glucose metabolism links astroglial
16 mitochondria to cannabinoid effects. *Nature* 583, 603-608.

17 Johnson, M.B., Young, A.D., and Marriott, I. (2016). The Therapeutic Potential
18 of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders.
19 *Front Cell Neurosci* 10, 296.

20 Kanellopoulos, A.K., Mariano, V., Spinazzi, M., Woo, Y.J., McLean, C., Pech,
21 U., Li, K.W., Armstrong, J.D., Giangrande, A., Callaerts, P., *et al.* (2020). Aralar
22 Sequesters GABA into Hyperactive Mitochondria, Causing Social Behavior
23 Deficits. *Cell* 180, 1178-1197 e1120.

1 Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., and
2 Watanabe, M. (2009). Endocannabinoid-mediated control of synaptic
3 transmission. *Physiol Rev* 89, 309–380.

4 Klapoetke, N.C., Murata, Y., Kim, S.S., Pulver, S.R., Birdsey-Benson, A., Cho,
5 Y.K., Morimoto, T.K., Chuong, A.S., Carpenter, E.J., Tian, Z., et al. (2014).
6 Independent optical excitation of distinct neural populations. *Nat Methods* 11,
7 338–346.

8 Knight, R.T. (2007). Neuroscience. Neural networks debunk phrenology.
9 *Science* 316, 1578-1579.

10 Koch, M., Varela, L., Kim, J.G., Kim, J.D., Hernandez-Nuno, F., Simonds, S.E.,
11 Castorena, C.M., Vianna, C.R., Elmquist, J.K., Morozov, Y.M., et al. (2015).
12 Hypothalamic POMC neurons promote cannabinoid-induced feeding. *Nature*
13 519, 45–50.

14 Lahuna, O., and Jockers, R. (2018). [Mitochondrial signaling of G protein-
15 coupled receptors]. *Biol Aujourd'hui* 212, 21-26.

16 Lemberger, T., Parlato, R., Dassel, D., Westphal, M., Casanova, E., Turiault,
17 M., Tronche, F., Schiffmann, S.N., and Schutz, G. (2007). Expression of Cre
18 recombinase in dopaminergic neurons. *BMC Neurosci* 8, 4.

19 Lever, I.J., and Maccagno, M. (2002). CB(1) receptor antagonist SR141716A
20 increases capsaicin-evoked release of Substance P from the adult mouse
21 spinal cord. *Br J Pharmacol* 135, 21-24.

22 Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression
23 data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
24 *Methods* 25, 402-408.

1 Makrecka-Kuka, M., Krumschnabel, G., and Gnaiger, E. (2015). High-
2 Resolution Respirometry for Simultaneous Measurement of Oxygen and
3 Hydrogen Peroxide Fluxes in Permeabilized Cells, Tissue Homogenate and
4 Isolated Mitochondria. *Biomolecules* 5, 1319-1338.

5 Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich,
6 A., Azad, S.C., Cascio, M.G., Gutierrez, S.O., van der Stelt, M., *et al.* (2003).
7 CB1 cannabinoid receptors and on-demand defense against excitotoxicity.
8 *Science* 302, 84-88.

9 Marsicano, G., and Kuner, R. (2008). Anatomical distribution of receptors,
10 ligands and enzymes in the brain and the spinal cord: circuitries and
11 neurochemistry. In *Cannabinoids and the brain*, A. Kofalvi, ed. (New York:
12 Springer), pp. 161-202.

13 Martin, J.L., Gadegbeku, B., Wu, D., Viallon, V., and Laumon, B. (2017).
14 Cannabis, alcohol and fatal road accidents. *PloS one* 12, e0187320.

15 Martinez, A., Macheda, T., Morgese, M.G., Trabace, L., and Giuffrida, A.
16 (2012). The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA
17 activation and dyskinetic behavior in 6-OHDA-treated rats. *Neurosci Res* 72,
18 236-242.

19 Metna-Laurent, M., Mondesir, M., Grel, A., Vallee, M., and Piazza, P.V. (2017).
20 Cannabinoid-Induced Tetrad in Mice. *Curr Protoc Neurosci* 80, 9 59 51-59 59
21 10.

22 Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schutz, G.,
23 Wotjak, C.T., Lutz, B., and Marsicano, G. (2007). Genetic dissection of
24 behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice.
25 *PLoS biology* 5, e269.

1 Nadal, X., La Porta, C., Andreea Bura, S., and Maldonado, R. (2013).
2 Involvement of the opioid and cannabinoid systems in pain control: New
3 insights from knockout studies. *European Journal of Pharmacology* 716, 142–
4 157.

5 Niswender, C.M., Willis, B.S., Wallen, A., Sweet, I.R., Jetton, T.L., Thompson,
6 B.R., Wu, C., Lange, A.J., and McKnight, G.S. (2005). Cre recombinase-
7 dependent expression of a constitutively active mutant allele of the catalytic
8 subunit of protein kinase A. *Genesis* 43, 109-119.

9 Oliveira da Cruz, J., Busquets-Garcia, A., Zhao, Z., Varilh, M., Lavanco, G.,
10 Bellocchio, L., Robin, L., Cannich, A., Julio-Kalajzić, F., Lesté-Laserre, T.,
11 Maitre, M., Drago, F., Marsicano, G., Soria-Gomez, E. (2020). Specific
12 Hippocampal Interneurons Shape Consolidation of Recognition Memory. *Cell*
13 *Reports*. 32(7): 108046. doi: 10.1016/j.celrep.2020.108046

14 Oshita, K., Inoue, A., Tang, H.B., Nakata, Y., Kawamoto, M., and Yuge, O.
15 (2005). CB(1) cannabinoid receptor stimulation modulates transient receptor
16 potential vanilloid receptor 1 activities in calcium influx and substance P
17 Release in cultured rat dorsal root ganglion cells. *J Pharmacol Sci* 97, 377-385.

18 Pagano Zottola, A.C., Soria-Gomez, E., Bonilla-del-Río, I., Muguruza, C.,
19 Terral, G., Robin, L.M., Oliveira da Cruz, J.F., Redon, B., Lesté-Lasserre, T.,
20 Tolentino-Cortes, T Puente, N., Barreda-Gómez, G Chaouloff, F., Callado, L.F.,
21 Grandes, P., Marsicano, G., Bellocchio, L. (2020). A new mutant mouse model
22 lacking mitochondrial-associated CB1 receptor. *Biorxiv*.

23 Pautrat, A., Rolland, M., Barthelemy, M., Baunez, C., Sinniger, V., Piallat, B.,
24 Savasta, M., Overton, P.G., David, O., and Coizet, V. (2018). Revealing a novel

1 nociceptive network that links the subthalamic nucleus to pain processing. *ELife*
2 7, e36607.

3 Paxinos, G., and Franklin, K.B.J. (2001). *The Mouse Brain in Stereotaxic*
4 *Coordinates* (S. Diego (USA): Academic Press).

5 Pertwee, R.G. (2001). Cannabinoid receptors and pain. *Progress in*
6 *neurobiology* 63, 569-611.

7 Prashad, S., and Filbey, F.M. (2017). Cognitive motor deficits in cannabis users.
8 *Curr Opin Behav Sci* 13, 1-7.

9 Puente, N., Bonilla-Del Río, I., Achicallende, S., Nahirney, P.C., and Grandes,
10 P. (2019). High-resolution Immunoelectron Microscopy Techniques for
11 Revealing Distinct Subcellular Type 1 Cannabinoid Receptor Domains in Brain.
12 *Bioprotocol* 9.

13 Qi, G., Mi, Y., and Yin, F. (2019). Cellular Specificity and Inter-cellular
14 Coordination in the Brain Bioenergetic System: Implications for Aging and
15 Neurodegeneration. *Front Physiol* 10, 1531.

16 Rajendran, L., Knolker, H.J., and Simons, K. (2010). Subcellular targeting
17 strategies for drug design and delivery. *Nat Rev Drug Discov* 9, 29-42.

18 Rangaraju, V., Calloway, N., and Ryan, T.A. (2014). Activity-driven local ATP
19 synthesis is required for synaptic function. *Cell* 156, 825-835.

20 Ray, A.P., Chebolu, S., Ramirez, J., and Darmani, N.A. (2009). Ablation of least
21 shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.
22 *Behavioral neuroscience* 123, 701-706.

23 Redon, B., Violleau, C., Georges, F., Marsicano, G., and Chaouloff, F. (2020).
24 The ergogenic impact of the glucocorticoid prednisolone does not translate into
25 increased running motivation in mice. *Psychoneuroendocrinology* 111, 104489.

1 Rozenfeld, R., and Devi, L.A. (2008). Regulation of CB1 cannabinoid receptor
2 trafficking by the adaptor protein AP-3. *FASEB journal : official publication of the*
3 *Federation of American Societies for Experimental Biology* 22, 2311-2322.

4 Ruehle, S., Remmers, F., Romo-Parra, H., Massa, F., Wickert, M., Wortge, S.,
5 Haring, M., Kaiser, N., Marsicano, G., Pape, H.C., and Lutz, B. (2013).
6 Cannabinoid CB1 Receptor in Dorsal Telencephalic Glutamatergic Neurons:
7 Distinctive Sufficiency for Hippocampus-Dependent and Amygdala-Dependent
8 Synaptic and Behavioral Functions. *The Journal of neuroscience : the official*
9 *journal of the Society for Neuroscience* 33, 10264-10277.

10 Sales-Carbonell, C., Rueda-Orozco, P.E., Soria-Gomez, E., Buzsaki, G.,
11 Marsicano, G., and Robbe, D. (2013). Striatal GABAergic and cortical
12 glutamatergic neurons mediate contrasting effects of cannabinoids on cortical
13 network synchrony. *Proceedings of the National Academy of Sciences of the*
14 *United States of America* 110, 719-724.

15 Simpson, D. (2005). Phrenology and the neurosciences: contributions of F. J.
16 Gall and J. G. Spurzheim. *ANZ J Surg* 75, 475-482.

17 Skalhegg, B.S., and Tasken, K. (2000). Specificity in the cAMP/PKA signaling
18 pathway. Differential expression, regulation, and subcellular localization of
19 subunits of PKA. *Front Biosci* 5, D678-693.

20 Soria-Gomez, E., Bellocchio, L., Reguero, L., Lepousez, G., Martin, C.,
21 Bendahmane, M., Ruehle, S., Remmers, F., Desprez, T., Matias, I., *et al.*
22 (2014). The endocannabinoid system controls food intake via olfactory
23 processes. *Nature neuroscience* 17, 407-415.

24 Steiner, H., Bonner, T.I., Zimmer, A.M., Kitai, S.T., and Zimmer, A. (1999).
25 Altered gene expression in striatal projection neurons in CB1 cannabinoid

1 receptor knockout mice. Proceedings of the National Academy of Sciences of
2 the United States of America 96, 5786-5790.

3 Steinhoff, M.S., von Mentzer, B., Geppetti, P., Pothoulakis, C., and Bunnett,
4 N.W. (2014). Tachykinins and their receptors: contributions to physiological
5 control and the mechanisms of disease. *Physiol Rev* 94, 265-301.

6 Szabo, B., Wallmichrath, I., Mathonia, P., and Pfreundtner, C. (2000).
7 Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars
8 reticulata. *Neuroscience* 97, 89-97.

9 Taylor, A.M., Becker, S., Schweinhardt, P., and Cahill, C. (2016). Mesolimbic
10 dopamine signaling in acute and chronic pain: implications for motivation,
11 analgesia, and addiction. *Pain* 157, 1194-1198.

12 Terral, G., Busquets-Garcia, A., Varilh, M., Achicallende, S., Cannich, A.,
13 Bellocchio, L., Bonilla-Del Río, I., Massa, F., Puente, N., Soria-Gomez, E., et al.
14 (2019). CB1 Receptors in the Anterior Piriform Cortex Control Odor Preference
15 Memory. *Current Biology* 29, 2455-2464.e5.

16 Vallee, M., Vitiello, S., Bellocchio, L., Hebert-Chatelain, E., Monlezun, S.,
17 Martin-Garcia, E., Kasanetz, F., Baillie, G.L., Panin, F., Cathala, A., *et al.*
18 (2014). Pregnenolone can protect the brain from cannabis intoxication. *Science*
19 343, 94-98.

20 Valsecchi, F., Konrad, C., and Manfredi, G. (2014). Role of soluble adenylyl
21 cyclase in mitochondria. *Biochim Biophys Acta* 1842, 2555-2560.

22 Vos, M., Lauwers, E., and Verstreken, P. (2010). Synaptic mitochondria in
23 synaptic transmission and organization of vesicle pools in health and disease.
24 *Front Synaptic Neurosci* 2, 139.

1 Wilson, R.I., Kunos, G., and Nicoll, R.A. (2001). Presynaptic specificity of
 2 endocannabinoid signaling in the hippocampus. *Neuron* 31, 453-462.

3 Woodhams, S.G., Chapman, V., Finn, D.P., Hohmann, A.G., and Neugebauer,
 4 V. (2017). The cannabinoid system and pain. *Neuropharmacology* 124, 105-
 5 120.

6 Zaelzer, C., Gizowski, C., Salmon, C.K., Murai, K.K., and Bourque, C.W.
 7 (2018). Detection of activity-dependent vasopressin release from neuronal
 8 dendrites and axon terminals using sniffer cells. *J Neurophysiol* 120, 1386-
 9 1396.

10 Zhao, Z., Soria-Gomez, E., Varilh, M., Covelo, A., Julio-Kalajzic, F., Cannich,
 11 A., Castiglione, A., Vanhoutte, L., Duveau, A., Zizzari, P, Beyeler, A., Cota, D.,
 12 Bellocchio, L., Busquets-Garcia, A., Marsicano, G. (2020). A novel cortical
 13 mechanism for top-down control of water intake. *Curr Biol* 30, 4789-4798.

14 Zhou, F.M. (2016). The Substantia Nigra Pars Reticulata. In *Handbook of*
 15 *Behavioral Neuroscience*, (Elsevier), pp. 293–316.

16

Figure 1

Figure 2

Figure 3

Figure 4

Figure S1

Figure S2**A** **B** **C** **D**

Figure S2 (cont)

Figure S3

Figure S3 (cont)

Figure S4